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ABSTRACT 
Nutritional factors play a life-long role in human health. Indeed, there is growing 
evidence that one of the mechanisms by which nutrients and bioactive compounds affect 
metabolic traits is epigenetics. Complex interactions among food components and 
histone modifications, DNA methylation, non-coding RNA expression and chromatin 
remodeling factors lead to a dynamic regulation of gene expression that controls the 
cellular phenotype. Although perinatal period is the time of highest phenotypic 
plasticity, contributing largely to developmental programming, also during adulthood 
there is evidence about a nutritional influence on epigenetic regulation. Similarly to type 
2 diabetes, hypertension, atherosclerosis and other metabolic disorders, obesity 
predisposition and weight loss outcomes have been repeatedly associated to changes in 
epigenetic patterns. Different non-nutritional risk factors that usually accompany 
obesity seem also to be involved in these epigenetic modifications, especially 
hyperglycemia, inflammation, hypoxia and oxidative stress. There are currently three 
major objectives in epigenetic research in relation to obesity: to search for epigenetic 
biomarkers to predict future health problems or detect the individuals at most risk, to 
understand the obesity-related environmental factors that could modulate gene 
expression by affecting epigenetic mechanisms, and to study novel therapeutic 
strategies based on nutritional or pharmacological agents that can modify epigenetic 
marks. At this level, the major tasks are: development of robust epigenetic biomarkers 
of weight regulation, description of those epigenetic marks more susceptible to be 
modified by dietary exposures, identification of the active ingredients (and the doses) 
that alter the epigenome, assessment of the real importance of other obesity-related 
factors on epigenetic regulation, determination of the period of life in which best results 
are obtained, and understanding of the importance of the inheritance of these epigenetic 
marks.  
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1. Introduction 
The prevalence of obesity is increasing in every country of the world and only in the 
United States there are now more than 100 million individuals with overweight or 
obesity (Lopez et al., 2012). The onset of obesity results from an imbalance between 
energy intake and expenditure, being this pandemic largely attributable to the high 
availability of foods with high caloric content coupled with the adoption of a sedentary 
lifestyle. The inter-individual differences have been often ascribed to genetic variants 
that affect hundreds of genes related to energy metabolism (Hinney et al., 2010), but in 
the last years other factors have been described to take part in the equation and 
contribute to increase (or decrease) the susceptibility to gain weight or to develop 
obesity-related complications, including cardiovascular diseases, type 2 diabetes, or 
steatohepatitis. Some of these alternative putative contributors that have been recently 
reviewed (McAllister et al., 2009) include infections, sleep debt, reduction in variability 
of ambient temperatures, endocrine disruptors, increasing maternal age, greater 
fecundity among people with higher adiposity, assortative mating, pharmaceutical 
iatrogenesis, intrauterine and intergenerational effects, and epigenetics. As the past 
decades have been accompanied with unprecedented transitions in our lifestyle, the 
study of these alternative contributors to obesity epidemics is being actively pursued 
(Symonds et al., 2011). Some of them are represented in figure 1. 
Epigenetics, that has been defined as heritable changes in gene expression that cannot 
be explained by changes in DNA sequence (Christensen and Marsit, 2011), has been 
subject of special interest in the last years mainly because there is evidence on the 
impact of different nutrients, environmental compounds and metabolic situations on the 
epigenome, which may lead to the development of more personalized disease 
prevention and treatment strategies (Campion et al., 2010; Choi and Friso, 2010). As 
epigenetic changes are modulated by environmental exposures, epigenetics is 
considered the interface between genetics and the environment. In this sense, only 
environmental (including nutritional) factors are able to explain the phenotypical and 
epigenetic differences reported in monozygotic twins, which increase over the years 
(Fraga et al., 2005). In fact, epigenetic mechanisms are good candidates for explaining 
the role of the diet and other environmental conditions of parents and grandparents, or 
the influence of perinatal dietary exposures as determinants of later health outcomes 
(Zeisel, 2009). These altered epigenetic marks are implicated in the aetiology of cancer, 
that is being extensively studied, but also of chronic non-communicable metabolic 
diseases like obesity, diabetes and cardiovascular diseases. 
The main epigenetic mechanisms that regulate gene expression in placental mammals 
are 1) DNA methylation, predominantly in the fifth carbon in the cytosines that are 
followed by a guanine, 2) a variety of histone modifications that include methylation, 
acetylation, ubiquitination and sumoylation of lysine, phosphorylation of serine and 
threonine, and methylation of arginine, 3) other nuclear proteins that are critical for 
epigenetic gene regulation (such as chromatin remodeling complexes, effector proteins 
with various binding modules for different modifications, and insulator proteins), 4) 
genomic imprinting, by which the expression of a gene is limited to one of the two 
parental alleles, 5) non-coding RNAs including microRNAs (miRNAs), which can bind 
to and regulate multiple mRNAs, and 6) non-covalent mechanisms, such as physical 
alterations in nucleosomal positioning via nucleosome remodelers or replacement of 
canonical histone proteins with specialized histone variants such as H3.3 and H2A.Z 
(Kim JK et al., 2009; Sharma et al., 2010). 
As described in figure 2, the most extensively studied epigenetic modifications in 
mammals are miRNAs, DNA methylation and covalent histone modifications 
(Lavebratt et al., 2011). The last two mechanisms provide a stable gene silencing 
mechanism that plays an important role in regulating gene expression and chromatin 
architecture. Although these epigenetic marks are stable and tissue-specific, studies of 
identical twins have found an age-dependent progression of epigenetic change, with 
greater differences in global DNA methylation in older than in younger twins (Fraga et 
al., 2005). The plasticity, tissue-specific nature, and variability of epigenetic marks vary 
across individuals and not only aging but also other environmental exposures alter 
tissue-specific DNA methylation and could be implicated in the susceptibility to 
diseases like cancer, neurological problems or metabolic disorders (Chistensen and 
Marsit, 2009). The reversible nature of epigenetic aberrations has led to the emergence 
of new therapeutic epigenetic approaches that might be used to counter detrimental 
environmental exposure effects (Costello et al., 2009). In this sense, different molecules 
are being studied in cancer research due to their modulatory action on epigenetic 
processes, including azacitidine (Vidaza) and decitabine (Dacogen), two 
methyltransferase inhibitors that reduce DNA methylation, vorinostat or SAHA 
(Zolinza) and romidepsin (Istodax), which inhibit histone deacetylases. These molecules 
have been approved by the FDA for cancer treatment as they prolong cell survival and 
are less toxic than conventional chemotherapy (Boumber and Issa, 2011). In this sense, 
even better results have been obtained in cancer clinical trials when the treatment 
combines DNA methylation inhibitors and histone deacetylase inhibitors (Fandy et al., 
2009; Stathis et al., 2011). 
However, there are two important concerns regarding this therapeutic approach. The 
first one is the lack of specificity, as epigenetic modifications are used by the different 
tissues and cell lines and by both normal and impaired cells to regulate gene expression 
(Humeniuk et al., 2009). The other concern is related to the amount of change that must 
be reverted. In cancer, it is usual to observe sharp changes between both normal and 
malignant cells, so that epigenetic drugs can be used in relatively high doses to reverse 
the abnormal methylation patterns and slow down or stop cancer cell growth (Alvarez et 
al., 2010). In relation to body weight, the reports that have analyzed differences in the 
percentage of methylation in cytosines of different genes have shown variations of 
about 10-20% at the most (Bouchard et al., 2010; Milagro et al., 2011). On paper, it 
seems difficult to modulate the epigenetic drug doses to revert such subtle differences, 
but the identification in the last years of several nutrients and food compounds that are 
able to slightly modify the epigenetic patterns of different cell lines and tissues are 
encouraging in order to look for functional foods that could help to combat or prevent 
metabolic diseases (vel Szic et al., 2010). Thus, the large differences in DNA 
methylation observed between human preadipocytes and mature adipocytes (Zhu 2012) 
suggest that epigenetics plays an important role in the process of adipocyte 
differentiation. Other epigenetic mechanisms that play an important role in adipogenesis 
are histone methylation and demethylation (Okamura et al., 2010), poly(ADP-
ribosyl)ation (Erener et al., 2012), and acetylation and deacetylation (Kim SJ et al., 
2011; Chatterjee et al., 2011). For example, the promoter of the PPARγ gene, a key 
transcriptional regulator of adipogenesis, is hypermethylated in 3T3-L1 preadipocytes, 
but is gradually demethylated upon induction of differentiation (Fujiki et al., 2009). 
Finally, the importance of epigenetic mechanisms in the regulation of energy balance is 
supported by the fact that 256 new candidate imprinted genes have been identified in the 
adult mouse hypothalamus, the key regulator of appetite and many endocrine functions 
(Gregg et al., 2010). 
Obesity and its related complications have been repeatedly associated with epigenetic 
alterations. Thus, methylation changes in blood leukocyte DNA have been observed in 
obese adolescents (Wang X et al., 2010), whereas methylation of TFAM gene promoter 
in peripheral white blood cells has been associated with insulin resistance in adolescents 
(Gemma et al., 2010). In type 2 diabetes, the large number of genes presenting 
differential methylation status in skeletal muscle from normal glucose-tolerant and 
diabetic subjects suggests that DNA methylation is an important contributor to the 
development of this pathology and associated complications (Barrès et al., 2009). In this 
sense, insulin gene expression is known to be regulated by cytosine methylation, and 
pathologic methylation patterns have been suggested to contribute to the development 
of diabetes (Kuroda et al., 2009). Some of the genes related to metabolic regulation that 
have been reported to be regulated by DNA methylation are shown in Table 1. 
Additionally, as obesity is a complex disease that usually appears as a polygenic 
condition affected by environmental factors (mainly unbalanced dietary patterns and 
physical inactivity), it is the combination of genotype and epigenotype that will best 
assist to reveal diet associations with susceptibility to obesity and other related disorders 
(Martinez et al., 2012). 
In the current review, particular emphasis will be placed on the following aspects: 
- identification of epigenetic marks that could be used as biomarkers in the diagnosis 
and prognosis of obesity and other non-communicable diseases. Some of these marks 
could be inherited from one or both carrier parents, and thus be detected early in life 
and, in some cases, steps might be taken to overcome them. Very interestingly, some 
epigenetic marks can be affected by environmental factors during in utero and perinatal 
stages, including maternal diet, uterine blood flow, lactation, and maternal nursing 
behavior (Hanley et al., 2010; Hanson et al., 2011a), so that they could be properly 
handled. Finally, others could be acquired during the process of aging due to metabolic, 
environmental and dietary factors that need to be thoroughly studied. 
- presentation of some of the environmental factors related to obesity that could 
modulate gene expression by affecting epigenetic mechanisms. Some of these 
epigenetic modifications may have a causative role in the development of obesity-
related complications and could also influence the response to anti-obesity treatments 
through diet and physical activity. It is of great interest to broaden the knowledge on the 
environmental factors that affect epigenetic mechanisms related to obesity in order to 
prevent unhealthy diets and attitudes and to personalize treatments, for which new in 
vitro and in vivo experiments must be designed and performed. 
- suggestion of possible mechanisms (that must be deeply investigated) by which the 
obesity-prone epigenetic alterations could be neutralized by the use of drugs or, more 
interestingly, by favoring the intake of protective compounds being able to module the 
epigenetic processes. 
 
2. Search for epigenetic biomarkers  
Obesity biomarkers have a great potential to better characterize the obesity phenotype, 
which may be relevant for assessing the risk of diabetes and CVD beyond 
anthropometric and biochemical parameters or for personalizing weight loss plans. 
However, most current biomarkers have only modest predictive value, and there is a 
need to identify additional biomarkers from new biological pathways by employing the 
new platforms for profiling DNA, RNA, proteins and metabolites (May and Wang, 
2008). In this sense, epigenetic marks, such as DNA methylation patterns and miRNAs 
transcription, are suitable for sensitive detection, are very stable phenomena in tissues 
and blood cells, and have a long history in oncology. Thus, methylated CpG islands of 
p16, Septin9, and MGMT are being used as predictive biomarkers for cancer diagnosis, 
classification, development, prognosis and chemosensitivity (Deng et al., 2010).  
In obesity, the identification of epigenetic biomarkers that could help to detect at an 
early age those individuals more susceptible to later develop obesity or visceral 
adiposity may allow to prevent and personalize its progress and manifestations 
(Campion et al., 2009a). In a very interesting article, Feinberg et al. (2010) have 
identified four variably methylated regions (VMRs) that show covariation with body 
mass index and are located in or near genes implicated in regulating body weight or 
diabetes. Due to the long time that is needed to perform studies of prognostic 
biomarkers of obesity in humans, research has been focused on explaining individual 
differences in weight loss after an energy-restriction intervention (Campion et al., 
2009b; Bouchard et al., 2010; Milagro et al., 2011; Cordero et al., 2011a). The most 
comprehensive studies have performed a DNA methylation array study comparing 
samples from responders and non-responders to a hypocaloric diet treatment followed 
by a validation with more individuals and employing a second technique, such as 
Sequenom EpiTYPER (Bouchard et al., 2010; Milagro et al., 2011). Other studies have 
used more focused approaches, such as direct bisulfite sequencing (Campion et al., 
2009) or methylation-specific PCR (MSP) (Cordero et al., 2011a), and have found that 
several CpGs located in the promoters of leptin and TNF-α, when measured in blood 
cells, could be used as biomarkers of weight loss. In this sense, although it is of great 
interest to study the baseline epigenetic differences in obesity-related tissues, such as 
adipose or liver, peripheral blood mononuclear cells (or otherwise white cells) are being 
preferably used because of their less-invasive nature, low risk, and high diagnostic 
accuracy (Widschwendter et al., 2008). However, the study of specific DNA 
methylation in serum or whole blood should be encouraged as its economic cost is low, 
its availability is very easy and its prognostic significance has been demonstrated in 
different types of cancer, such as lung (Fujiwara et al., 2005)  or gastric adenocarcinoma 
(Al-Moundhri et al., 2010). The biological significance of whole-genome methylation 
appears irrelevant and usually lacks of prognostic value in metabolic diseases because a 
low sensibility. However, it has been reported as a dietary biomarker in the comparison 
of vegetarian vs omnivorous subjects (Geisel et al., 2005) and global DNA methylation 
was significantly higher in coronary artery disease patients than in controls, which was 
correlated with plasma homocysteine levels (Sharma et al., 2008). In this sense, global 
DNA methylation in peripheral blood leukocytes has been proposed as a biomarker for 
cardiovascular disease risk (Kim et al., 2010). 
In the field of prognostic biomarkers of obesity, it is necessary to take advantage of 
prospective cohort studies that follow over time a group of individuals and that collect 
samples from an early age and compare the modifications with samples from the same 
subjects several years later. For this purpose, methylation microarrays or, in a near 
future, high-throughput sequencing are the tools of choice. In this sense, large-scale 
epigenome-wide association studies (EWASs) that evaluate hundreds of thousands of 
CpGs in thousands of individuals (the same model as GWAS) present novel 
opportunities for finding epigenetic marks that could be involved in the development of 
metabolic diseases (Rakyan et al., 2011a). The first systematic analysis of the temporal 
origins of disease-associated epigenetic variation for any human complex disease has 
been published for type 1 diabetes by following an EWAS strategy in discordant 
monozygotic twin pairs (Rakyan et al., 2011b). With a more modest approach, and 
using Sequenom MassARRAY, it has been recently reported that perinatal epigenetic 
analyses in umbilical cord tissue DNA may be used to identify individual vulnerability 
to later obesity at age 9 years (Godfrey et al., 2011). Similarly, altered DNA 
methylation of TACSTD2 gene was observed in preterm children when compared to 
term born ones, which was associated with rapid postnatal growth and increased risk of 
adiposity at 9-15 years of age (Groom et al., 2012). 
The other interesting point concerning the search for epigenetic biomarkers in obesity is 
the possibility of identifying those individuals that have more susceptibility to develop 
metabolic impairments with respect to those that are less prone. Similarly to prognostic 
biomarkers, prospective cohort studies that follow over time a group of individuals are 
necessary. 
Finally, once that it is clear that obesity is associated to changes in DNA methylation in 
different gene promoters, such as in serotonin transporter gene, that has a critical role in 
regulating food intake, body weight and energy balance (Zhao et al., 2012), there is 
interest in finding diagnostic biomarkers that help to differentiate individuals that are 
developing a metabolic complication with respect to the rest of the population. For this 
purpose, studies comparing individuals suffering the complication in comparison with 
control subjects have been performed. Thus, an excess of differentially methylated sites 
in genomic regions of subjects with or without type 2 diabetes mellitus, including a 
CpG site in the first intron of the FTO gene has been described (Toperoff et al., 2012). 
FTO is the most important human obesity gene and its mRNA levels in the arcuate 
nucleus are regulated by feeding and fasting (Gerken et al., 2007). Interestingly, it 
encodes a 2-oxoglutarate-dependent nucleic acid demethylase and may have a potential 
role in DNA methylation regulation (Gerken et al., 2007). A similar approach has 
revealed that 187 genes were differentially methylated between diabetes patients with 
end stage renal disease and diabetes patients without nephropathy (Sapienza et al., 
2011). 
As a conclusion, epigenetic marks could be useful to personalize nutrition, to early 
detect those individuals with more risk to develop metabolic disorders or to better 
respond to a treatment. However, a wider approach should be adopted, and epigenetic 
marks have to be studied at the same time that SNPs, miRNA expression and mRNAs in 
order to decipher the interactions among DNA sequence, epigenetics and gene 
expression, always taken into account the diet and other environmental factors. 
 
3. Nutritional factors 
In the last years, a number of studies have related different dietary patterns, nutrients 
and food components with epigenetic processes that regulate gene expression and may 
contribute to an increased susceptibility to develop obesity and other metabolic 
disorders (Table 2). They are analyzed more in detail in the following chapters. 
3.1. Calorie restriction and low protein-diets 
There are several epidemiological and animal studies linking suboptimal early nutrition 
and poor growth in utero with increased risk of hypercholesterolemia, hypertension, 
type 2 diabetes and obesity in adulthood (Martin-Gronert and Ozanne, 2010; Seki et al., 
2012). In relation to the multiple mechanisms implicated, it is clear that epigenetics 
plays a clue role. Both calorie restriction and low protein diets are known to induce 
epigenetic modifications and metabolic alterations that persist in the adult. Thus, a 
moderate restriction of energy intake during the periconceptional period is considered a 
stressor and is accompanied by increased adrenal mass and an increased cortisol 
response to stress, but also by epigenetic modification such as decreased methylation in 
IGF2/H19 gene in the adrenal gland (Zhang et al., 2010). Energy restriction also 
induces changes in covalent histone modifications. Thus, chromatin 
immunoprecipitation assays of the GLUT4 promoter revealed that calorie restriction 
increases histone 4 acetylation in adipose tissue of mice fed a high-fed diet, which was 
not observed in mice that followed a treadmill exercise (Wheatley et al., 2011). The first 
example of an association between periconceptional energy restriction and DNA 
methylation in humans comes from the deep analysis of people born during the Dutch 
Hunger Winter of 1944-1945, that shows persistent epigenetic differences associated 
with prenatal exposure to famine (Heijmans et al., 2008). 
The article by Lillycrop et al. (2008), showing that a maternal protein-restricted diet 
persistently alters the methylation of specific cytosines in the hepatic PPARα promoter 
of the offspring, is a milestone in metabolic programming studies, establishing that 
methylation changes due to prenatal nutrition persist in adults. Subsequent studies have 
deepened into this concept. Thus, in liver, maternal low protein intake alters gene 
expression of Igf2 and H19 by regulating DNA methylation (Gong et al., 2010) and 
induces changes in histone acetylation and methylation that affect genes regulating the 
amino acid response pathway (Zhou and Pan, 2011). Maternal low protein diet also 
elevates cholesterol in the offspring and induces changes in liver histone methylation 
status (Sohi et al., 2011). In skeletal muscle, it increases acetylated histone 3 and 
acetylated histone 4 at the C/EBPβ (Zheng et al., 2011b) and GLUT4 promoter regions 
(Zheng et al., 2011c) but only in female pups, indicating a sex-dependent adaptation. 
These studies suggest that adequate weight control and nutrient supply during 
pregnancy and lactation are crucial in metabolic programming and could be responsible 
of health problems related to metabolic and neurological functions. Maybe, some of 
these epigenetic mechanisms could help to explain why the prevalence of obesity, 
diabetes and cardiovascular diseases is higher in low-income neighbourhoods and is 
alarmingly rising in the less developed parts of the world. 
In adult humans, it has been reported that weight loss due to hypocaloric diets alter the 
methylation pattern of different genes in adipose tissue (Bouchard et al., 2010). In adult 
mice, the stress associated with caloric restriction seems to reprogram orexigenic 
pathways and alter the reward circuitry in the brain by affecting epigenetic mechanisms 
(Pankevich et al., 2010). In these mice, caloric restriction promotes binge-eating, and 
this result opens the door to study whether the yo-yo effect that makes weight loss 
maintenance so difficult may lie, at least in part, in epigenetic mechanisms. However, it 
is difficult to assess whether these epigenetic effects are directly caused by calorie 
restriction or by weight loss. In this sense, caloric restriction is the most effective 
environmental manipulation for extending lifespan in various animal models and is 
potentially involved in delaying aging-related degenerative diseases in humans 
(Speakman and Mitchell, 2011). One of the mechanisms by which caloric restriction 
affects lifespan is epigenetics, for example by mediation of sirtuins (Li Y et al., 2011), 
but this is a challenge that requires better understanding. 
  
3.2. Hypercaloric and high-fat diets 
In response to high-fat diets (HFD), the medial hypothalamus changes the expression of 
neuropeptides regulating feeding and energy metabolism whereas adipocyte and liver 
gene expression is strongly affected. Different epigenetic processes could participate in 
this dysregulation. In adult rodents, it has been demonstrated that long-term HFD has an 
effect on the methylation status of important obesity-related genes such as leptin in 
adipose tissue (Milagro et al., 2009) or melanocortin receptor 4 in brain (Widiker et al., 
2010), probably contributing to changes in gene expression and appetite regulation. On 
the other hand, whereas fasting decreases the number of acetylated histone H3- and H4-
positive cells in the ventrolateral subdivision of the ventromedial hypothalamus, HFD 
during four weeks results in increased expression of histone deacetylases HDAC5 and 
HDAC8 (Funato et al., 2011). These studies strongly suggest that hypercaloric diets 
alter the epigenetic mechanisms that regulate the expression of genes involved in the 
control of appetite and energy metabolism. 
As gestation and lactation are the periods of life more susceptible to epigenetic 
modifications that will persist in the adulthood, a number of studies have been 
performed during the perinatal period, especially in rodents. Thus, it has been reported 
that maternal overfeeding with HFD in rats induce a markedly obese phenotype in the 
offspring completely independent of postnatal nutrition (Howie et al., 2009) and also 
nonalcoholic steatohepatitis, which has been explained by impaired hepatic 
mitochondrial metabolism and up-regulated hepatic lipogenesis (Bruce et al., 2009). 
The origin of other metabolic diseases in the adult can be also related with maternal 
overnutrition, such as hypertension and hyperlipidemia (Elahi et al., 2009) or insulin 
resistance and diabetes (Samuelsson et al., 2008), and maternal HFD is associated with 
changes in hypothalamic regulation of body weight and energy homeostasis by altering 
the expression of leptin receptor, proopiomelanocortin, and neuropeptide Y in the adult 
offspring (Page et al., 2009). Nevertheless, not all the studies arise to the same 
conclusion. There are examples in which HFD given during gestation and lactation 
protects, at least partially, the offspring from excessive weight gain through different 
hypothalamic mechanisms (Couvreur et al., 2011). So, more studies are needed to 
elucidate the intrinsic mechanism related with these effects, and complementary studies 
in humans should be envisaged. In fact, it has been postulated that it is not dietary fat 
but maternal adiposity which induces hyperleptinemia, insulin resistance and increased 
body weight in offspring that persists into adulthood (White et al., 2009). Accoding to 
this hypothesis, maternal hyperglycemia, hyperinsulinemia, hyperleptinemia and 
inflammation would be potential mediator candidates (Rooney and Ozanne, 2011). 
These metabolic alterations in the offspring seem to be due, at least in part, by 
epigenetic modifications that persist during the adult life. Thus, neonatal overfeeding 
alters DNA methylation patterns of the hypothalamic promoter region of the main 
anorexigenic neuropeptide, proopiomelanocortin (POMC) (Plagemann et al., 2009). 
Maternal consumption of HFD can change the offspring’s' epigenetic marks in brain 
and alter gene expression of genes related to the mesocorticolimbic reward circuitry 
(dopamine and opioids), inducing a preference for palatable foods rich in sucrose and 
fat (Vucetic et al., 2010). Interestingly, these epigenetic modifications persist across at 
least two generations of offspring (Dunn and Bale, 2009) and could contribute to the 
rising prevalence of obesity that is observed in most countries. 
Although the intake of a hypercaloric diet is important, macronutrient distribution is 
also determinant in these epigenetic processes as has been demonstrated when adult rats 
were fed a pair-fed HFD and changes in fatty acid synthase promoter methylation were 
found in adipose tissue (Lomba et al., 2010). This kind of experiments is not easy to 
accomplish in humans, but it has been recently published that a dietary pattern 
characterized by a high intake of vegetables and fruits (called a “prudent” diet) may 
protect against the global DNA hypomethylation observed with a "Western" dietary 
pattern characterized by a high intake of meats, grains, dairy, oils, and potatoes (Zhang 
et al., 2011b). These results clearly demonstrate that obesity not only is the product of 
an energy imbalance, but that different epigenetic mechanisms are involved. These 
mechanisms would interact with age, the genetic background, dietary factors and other 
environmental influences to create interindividual differences in appetite regulation and 
obesity predisposition. 
 
3.3 Methyl donors 
Dietary methyl groups derive from foods containing methionine, serine, folate, biotin, 
and choline, that can transfer a methyl group to DNA and histones through S-
adenosylmethionine (SAM) and influence the expression of many genes (Zeisel, 2009; 
McKay and Mathers, 2011; Park et al., 2012). The remethylation of methionine from 
homocysteine requires zinc, selenium and vitamins B6 and B12. For example, 
methionine can be formed in the liver from homocysteine using methyl groups from 
methyltetrahydrofolate, or using methyl groups from betaine that are derived from 
choline (Zeisel, 2009). Thus, when humans are deprived of choline, they use more 
methyltetrahydrofolate to remethylate homocysteine and increase dietary folate 
requirements, but, conversely, when they are deprived of folate, they use more choline 
and increase dietary choline requirement. However, not all the individuals develop 
similar health problems with similar methyl donor intake because other factors are 
involved. Thus, single nucleotide polymorphisms (SNP) in genes regulating choline and 
folate metabolism increase or decrease the risk of dietary methyl donor deficiency 
(Zeisel, 2009). 
The importance of maternal methyl donor intake on changing the germ-line epigenetic 
state was first reported by Cropley et al. (2006) for the Avy agouti allele. A seminal 
article by Waterland et al. (2008) subsequently reported that methyl donor 
supplementation induces DNA hypermethylation during development and prevents 
transgenerational amplification of obesity in agouti viable yellow (Avy) mice. After 
that, many studies have analyzed the epigenetic effects of a diet deficient in methyl 
donors or with methyl donor supplementation during pregnancy in different metabolic 
diseases, including altered behavior in offspring (i.e, anxiety) through permanent 
changes in hippocampal DNA methylation (Konycheva et al., 2011). However, until 
now, few studies have associated perinatal methyl donors with long-term changes in 
body weight and metabolism. In sheep, low periconceptional supply of vitamin B12 and 
folate has been associated to fatter adult offspring, insulin-resistance and elevated blood 
pressure, which was accompanied by widespread epigenetic alterations to DNA 
methylation (Sinclair et al., 2007). In rats, perinatal methyl donor deficiency induces 
modest changes in the insulin axis of the fetus (Maloney et al., 2009) and programs 
glucose homeostasis in adult male but not female offspring (Maloney et al., 2011). Few 
studies have been performed in humans. In this sense, in India, a combination of high 
folate and low vitamin B12 concentrations in maternal diet was correlated with more 
risk to develop insulin resistance and obesity in the offspring (Yajnik et al., 2008) 
whereas in Nepal folate maternal supplementation was observed to reduce the risk of 
metabolic syndrome in the children (Stewart et al., 2009). Hence, more long-term 
intervention studies are needed to understand the benefits and risks of methyl donor 
doses in relation to obesity development because nutrient supplementation during 
pregnancy is widespread in the effort to combat anemia and other micronutrient 
deficiencies. 
Although methyl donor supply during the perinatal period is determinant for developing 
metabolic disturbances, also the intake in adulthood seems to be crucial. Thus, in adult 
mice, a methyl deficient diet results in the progressive accumulation of morphological 
changes in the liver similar to human non-alcoholic steatohepatitis that is accompanied 
by prominent epigenetic abnormalities, such as aberrant histone modifications and loss 
of genomic cytosine methylation, especially at major and minor satellites (Pogribny et 
al., 2009). In patients with nonalcoholic fatty liver disease, choline deficiency is 
associated with increased fibrosis (Guerrerio et al., 2012). 
Interestingly, it has been demonstrated that the fetal epigenetic programming is 
reversible in adult life by methyl donor supplementation. Thus, maternal programming 
of stress responses is reversed by the central infusion of methionine (Weaver et al., 
2005), whereas methyl donor supplementation prevents HFD-induced non-alcoholic 
fatty liver (Cordero et al., 2011b). However, we are far from being able to recommend 
supplementation or personalized intake of folate and other methyl donor because 
genotype (i.e., MTHFR 677C→T variant, CC vs. TT) seems to affect DNA methylation 
levels (Crider et al., 2011), and because aberrant changes in DNA methylation due to 
diet may lead to the development of age-associated diseases, including cancer (Kim KC 
et al., 2009). Thus, further research in animal models and human intervention studies 
are needed to accurately define the relationship between supraphysiological intake of 
methyl donors and chronic diseases, and much care must be taken when recommending 
these compounds during pregnancy. In this sense, some recent studies have focused on 
beneficial effects of betaine supplementation in adipose tissue dysfunction and insulin 
resistance (Wang Z et al., 2010), and folate supplementation in obese subjects with type 
2 diabetes (Gargari et al., 2011). 
 
3.4 Fatty acid and amino acids 
Many nutrients act as regulators of DNA methylation and histone modifications either 
by directly inhibiting enzymes that catalyze the processes, or by altering the availability 
of substrates necessary for the enzymatic reactions (Choi and Friso, 2010).  
Although one of the most widely used models of diet-induced obesity in animals is the 
intake of a high-fat diet, and some works have analysed the epigenetic modifications 
induced by this dietary approach in rodents (Lomba et al., 2010), it is still unknown the 
capacity of the different types of fatty acids to induce epigenetic modifications. Few 
studies have evidenced the role of n-3 and n-6 PUFA on DNA methylation, although 
there are examples concerning effects of eicosapentaenoic (Ceccarelli et al., 2011), 
docosahexaenoic (Kulkarni et al., 2011) and arachidonic (Kiec-Wilk et al., 2011) fatty 
acids on DNA methylation. It has been also reported that monounsaturated fatty acids 
can modulate other epigenetic mechanisms such as histone acetylation (Ku et al., 2011). 
Thus, more studies must be designed as it is well known that the dietary fatty acid 
composition is one of the main factors in the development of obesity and metabolic 
syndrome; particularly in relation to the beneficial effects associated to high long-chain 
n-3 PUFA intake, whose anti-inflammatory properties are being studied to reduce 
obesity-related low-grade inflammatory condition (Calder et al., 2011). 
One special case is butyrate, a short chain fatty acid produced during gut flora-mediated 
fermentation of dietary fiber sources that is rapidly absorbed and is the major energy 
source for colonocytes. This molecule induces high rates of in vitro apoptosis and cell 
cycle arrest presumably related to its strong HDAC inhibitory activity (Dashwood and 
Ho, 2007). As obesity is associated with important changes in gut microbiota 
composition, bacteria-produced butyrate could be one of the factors that links both 
phenomena through epigenetic mechanisms. Other short chain fatty acids produced by 
the gastrointestinal microbiota have been also associated with epigenetic changes that 
should be thoroughly analyzed. Thus, acetate, that enters the peripheral circulation to be 
metabolized by peripheral tissues, increases brain histone acetylation and inhibits 
histone deacetylase activity and expression (Soliman and Rosenberger, 2011), whereas 
propionate, that is the major donor molecule for histone propionylation, is involved in 
histone H3 lysine 23 propionylation in different cell lines (Liu et al., 2009). 
The amino acid that seems to play a major role in epigenetic mechanisms is methionine, 
the main source of methyl groups in biomethylation reactions and the key regulator of 
the one-carbon metabolism pathway (McKay and Mathers, 2011). However, the 
metabolism of other amino acids (serine, glycine and histidine) also plays an important 
role in provision of methyl donors for DNA and histone methylation (Wang et al., 
2012). However, neither methionine nor other amino acids are considered dietary 
factors that could affect the predisposition to suffer from obesity. Alternatively, changes 
in the circulating levels of several essential amino acids, particularly methionine, 
cysteine, tyrosine, phenylalanine and branched-chain amino acids, are apparently linked 
with obesity and insulin resistance and even occurs before the onset of type 2 diabetes 
(Adams, 2011). 
 
3.4. Minerals and vitamins 
A recent study performed in cord blood samples from offspring of Gambian women has 
reported that periconceptional maternal micronutrient supplementation with a 
supplement of 14 minerals and vitamins affect fetal gene promoter methylation that, in  
some cases, persist in infants at 9 months, with clear differences in patterns between the 
sexes (Khulan et al., 2012). Similar changes have been observed at imprinted loci in the 
same experiment (Cooper et al., 2012). However, this strategy might not be appropriate 
for preventing obesity because, in rats, multivitamin supplementation during pregnancy 
has been associated with increased food intake and obesity development in the offspring 
when fed a high-fat diet, which has been hypothesized to be mediated by epigenetic 
mechanisms (Szeto et al., 2009). As multivitamin supplementation is being used 
increasingly in modern societies, more studies must be designed to evaluate this issue. 
Different minerals have been associated with changes in epigenetic mechanisms 
regulating gene expression, such as selenium and zinc, which intervene in the regulation 
of DNMT activity and play a key role in the one-carbon pathway and in the activation 
of most HDACs (Ho et al., 2011). High levels of various inorganic and organic forms of 
heavy metals have been also related to epigenetic effects, including chromium, arsenite, 
lead, cadmium, copper and nickel (Cheng et al., 2012). Magnesium is other element that 
is able to modify epigenetic marks. Thus, magnesium deficiency in pregnant rats 
induces metabolic complications in the offspring by altering methylation of specific 
cytosines in the hepatic hydroxysteroid dehydrogenase-2 promoter (Takaya et al., 
2011). However, for the moment, few minerals have been associated to increased risk of 
developing obesity or insulin resistance. 
Magnesium intake has been repeatedly associated with obesity. Thus, low magnesium 
status has been associated with numerous pathological conditions characterized by 
chronic inflammatory stress, such as atherosclerosis, hypertension, osteoporosis, 
diabetes, and obesity (Nielsen, 2010). In animals there are numerous examples. Thus, 
maternal and postnatal magnesium status is important in the long-term programming of 
body adiposity and insulin secretion in rat offspring (Venu et al., 2008). However, in 
humans there are divergent conclusions about the effect of magnesium deficiency in 
obesity development. Even so, some intervention studies have found that oral 
magnesium supplementation improves insulin sensitivity in non-diabetic subjects with 
insulin resistance and in diabetic patients (Guerrero-Romero et al., 2004). 
Chromium is other element that has been related to obesity development. Thus, 
maternal chromium restriction significantly increases body weight and adiposity in rats 
probably by increasing stress and altering lipid metabolism in the offspring (Padmavathi 
et al., 2010), whereas chromium treatment is associated with a reduction in liver 
triglyceride levels, endoplasmic reticulum stress and insulin resistance in ob/ob obese 
mice (Sreejayan et al., 2008). However, despite the numerous studies performed in 
humans, there is no evidence that high-dose chromium treatment is effective in obese 
patients with type 2 diabetes (Kleefstra et al., 2006) and the involvement of epigenetic 
modifications has not been analyzed until now. An adventurous hypothesis postulate 
that, as chromium is an important modulator of insulin and glucose metabolism, 
increased exposure to chromium in preconceptional and fetal stage could lead to altered 
epigenetic control and altered endocrine and metabolic functioning (Ghambir and 
Phadke, 2011). 
Calcium is the mineral that seems to be more related to weight regulation (Zemel, 
2005). Thus, a systematic review of randomized clinical trials suggests that calcium 
supplementation generates small but statistically significant weight loss in overweight 
and obese individuals (Onakpoya et al., 2011). However, calcium has not been 
associated but indirectly with epigenetic modifications (Bocheva and Boyadjieva, 2011) 
and many more studies are necessary to discard that calcium could be a protective factor 
for obesity by acting through epigenetic mechanisms. 
Among micronutrients, vitamin C, vitamin E and carotenoids are being studied in 
obesity and related disorders because they are able to decrease the circulating 
concentrations of inflammatory and oxidative markers (Calder et al., 2011). Thus, there 
are studies that report a reduction in body weight and adiposity in cafeteria diet-induced 
obese rats when supplemented with ascorbic acid (Campion et al., 2008). Although 
more studies should be conducted, all these molecules are able to induce epigenetic 
changes. Thus, ascorbate promotes widespread DNA demethylation in human 
embryonic stem cells (Chung et al., 2010), whereas retinol alters histone 
phosphorylation levels in rat Sertoli cells (Moreira et al.,  2000). Vitamin E, lipoic acid 
and conjugated linoleic acids (CLA) require deeper analysis, although molecular 
modeling studies of all of them suggest a putative role as HDAC inhibitors (Dashwood 
and Ho, 2007). Nevertheless, it is necessary to design new in vitro and in vivo 
experiments with these antioxidants and other micronutrients to identify their epigenetic 
mechanisms of action. In summary, dietary supplementation with functional fatty acids, 
amino acids, vitamins and minerals might be useful as epigenetic therapies for 
metabolic disorders, although much work is needed with in vitro and animal models to 
understand the basic mechanisms of the specific nutrients. 
 
3.5. Polyphenols and other plant compounds 
Given the responsiveness of epigenetic marks to dietary factors, there are numerous 
studies that try to identify new plant compounds with effects on the epigenetic 
molecular processes in order to apply them in obesity prevention and treatment 
(Chaudhary et al., 2012). In a near future, we could talk about “epigenetic foods” that 
will be a kind of functional foods that contain bioactive compounds with capacity to 
modulate miRNA expression, DNA methylation or histone modifications. As in other 
issues related to epigenetics, this concept has been primarily developed in relation to 
cancer prevention, and several plant components are being studied in relation to 
apoptosis, cell cycle regulation, differentiation, inflammation, angiogenesis, and 
metastasis, as well as in stress response (Ross et al., 2011). In a similar way, 
understanding the epigenetic effects of dietary botanicals may provide insight on 
prevention strategies to reduce obesity prevalence and prevent its comorbidities. 
Polyphenols and other plant compounds are good candidates because they are 
considered potential therapeutic agents that can be used to prevent or treat obesity-
mediated inflammation and oxidative stress, as well as other metabolic disease-related 
health problems such as type 2 diabetes, atherosclerosis and hypertension (Fraga et al., 
2010). Among the bioactive compounds of plant origin that mediate epigenetic 
modifications there are agents like genistein (soybean), resveratrol (grapes), curcumin 
(turmeric), tea catechins (green tea), and sulforaphane (cruciferous vegetables) that have 
been considered in cancer prevention and therapy (Meeran et al., 2010; Li and 
Tollefsbol, 2010). 
Tea catechins, the most abundant of which is (–)-epigallocatechin-3-gallate (EGCG), 
are a group of flavonoids considered as one of the most promising treatments for 
metabolic syndrome. Thus, EGCG treatment in mice significantly reduces body weight 
gain, blood glucose levels and insulin resistance, decreases liver damage and liver 
triglyceride levels, and attenuates plasma cholesterol and inflammatory cytokines such 
as MCP-1, CRP or IL-6 (Chen et al., 2011). In obese KK-ay mice EGCG decreases 
glucose level and increases glucose tolerance in animals and, as in 3T3-L1 adipocytes, 
reduces ROS content (Yan et al., 2012). Some of these effects are surely mediated by 
epigenetic mechanisms as it is well known that EGCG is able to inhibit DNA 
methylation in different human cancer cell lines (Fang et al., 2003). One of the 
mechanisms of EGCG appears to be the direct inhibition of DNA methyltransferases 
(DNMT) by interaction with the catalytic site of the DNMT1 molecule (Fang et al., 
2003; Li and Tollefsbol, 2010), but it also acts by inhibiting histone acetyltransferase 
activity (Choi et al., 2009). 
Genistein is a flavonoid occurring in soybean that can act as an endocrine-disrupting 
substance playing a role in the etiology of obesity. However, at certain doses and 
dependent of sex and age, it could also inhibit adipogenesis in vitro in a similar way to 
female hormone estrogen (Dang, 2009). A seminal study of Dolinoy et al. (2006) 
showed that maternal genistein supplementation in mice during early embryonic 
development shift the coat color of heterozygous yellow agouti (Avy/a) offspring, 
which was significantly associated with increased methylation in a retrotransposon 
upstream of the transcription start site of the Agouti gene. In this model, genistein 
decreased ectopic Agouti expression and protected offspring from obesity in adulthood 
by altering the epigenome. Similarly, in nonhuman primates, soy protein and 
isoflavones improve body weight, insulin sensitivity and lipid profiles and modify the 
DNA methylation patterns in liver and muscle (Howard et al., 2011).  
Curcumin, a polyphenol occurring in turmeric with potent anti-inflammatory activity, is 
one of the natural compounds that have more potential as antiobesity treatment since, in 
vitro, is able to suppress 3T3-L1 differentiation and cause apoptosis (Ejaz et al., 2009). 
In HFD-fed mice, curcumin supplementation reduces body weight gain and adiposity 
probably by increasing oxidation and by decreasing fatty acid esterification in adipose 
tissue (Ejaz et al., 2009). In HFD-fed rats, the beneficial effect of curcumin is mediated 
by attenuating lipogenic gene expression in the liver and the inflammatory response in 
the adipose tissue (Shao et al., 2012). However, although curcumin is able to modulate 
histone deacetylases and acetyltransferases, DNA methyltransferase I, and miRNAs 
(Reuter et al., 2011), until now no studies have analyzed the involvement of curcumin-
induced epigenetic mechanisms in obesity models. An interesting precedent is the study 
of Yun et al., (Yun et al., 2011), in which curcumin decreased hyperglycemia-induced 
cytokine production in monocytes via epigenetic changes involving NFκB, including a 
decrease of HAT activity, p300 level and acetylated CBP/p300 gene expression, and the 
activation of HDAC2. 
Resveratrol is a stilbenoid with potent free radical scavenger properties that shows 
beneficial effects on type 2 diabetes and cardiovascular diseases, sharing some healthy 
actions with caloric restriction (Camins et al., 2010). Among other effects, this 
compound decreases hepatic steatosis severity in rats (Bujanda et al., 2008) and exerts 
an inhibitory effect on insulin secretion (Szkudelski, 2007). Although antiobesity 
actions of resveratrol have been extensively described in isolated adipocytes and in 
mice, including increased lipolysis and reduced lipogenesis in mature adipocytes, 
decreased adipogenesis and viability in maturing preadipocytes or protection from 
HFD-induced weight gain in mice (Baile et al., 2011), for the moment there are no big 
intervention trials showing similar effects in humans. Apart from its strong antioxidant 
activity, resveratrol is a potent activator of sirtuin 1, a (NAD(+))-dependent histone 
deacetylase that modulates gene expression in all the tissues (Camins et al., 2010). 
However, more information is needed about resveratrol bioavailability and mechanisms 
of action because some nutraceutical formulations containing resveratrol are widely 
available in the market. 
Different organosulfur compounds have been reported to exert anticarcinogenic effects 
probably acting through the inhibition of histone deacetylase activity (Nian et al., 2009). 
The most interesting natural molecules are sulforaphane, an isothiocyanate found in 
cruciferous vegetables that shows beneficial properties on human colon, prostate, and 
breast cancer cells, and garlic organosulfur compounds, such as diallyl disulfide, that 
are metabolized to allyl mercaptan and induce histone hyperacetylation in human colon 
cancer cells (Nian et al., 2009). Although no reports have demonstrated the obesity 
protective effects of sulforaphane in animal models, this isothiocyanate is effective in 
inhibiting adipocyte differentiation in culture through cell cycle arrest (Choi et al., 
2012) and, in relation to diabetes, reverses the oxygen intermediate production and 
inflammatory damage in experimental diabetic neuropathy and nephropathy (Negi et al., 
2011; Zheng et al., 2011a). On the other hand, although the mechanisms are not well 
known, garlic has been successfully used to reduce HFD-induced obesity in rodents 
(Lee et al., 2011). One of the potential causes could lie in the effects of diallyl trisulfide, 
which inhibits the differentiation of 3T3-L1 preadipocytes through ERK activation (Lii 
et al., 2011). However, it has also been reported that diallyl disulfide accelerates 3T3-L1 
preadipocyte differentiation because of its inhibition of histone deacetylase activity (Lee 
et al., 2007). Thus, more studies must be conducted to investigate the role of 
organosulfur compounds on adipogenesis and body weight regulation as well as the 
implication of epigenetic mechanisms in the process. 
Other bioactive compounds have been reported to inhibit DNMTs or modify histone 
acetylation, including lycopene, garcinol, luteolin, butein, apigenin, silymarin, 
rosmarinic acid, anacardic acid or baicalein (Campion et al., 2010; Meeran et al., 2010; 
Park et al., 2012). Some of them could have some benefits in the treatment or 
prevention of metabolic disorders. Moreover, there is currently great interest in 
identifying new plant compounds with epigenetic properties that could be applied as 
therapeutic agents in obesity (Chaudhary et al., 2012). So, numerous plant extracts and 
compounds are being screened for modulating histone modifying enzymes and DNMTs. 
The low bioavailability of most polyphenolic compounds and the impossibility of 
exactly determining the amounts included in the foods makes difficult to know the 
doses and the real effects of dietary polyphenols on DNA methylation in humans. So, 
more long-term studies testing the effects of different amounts of purified compounds, 
both in animals (periconceptually or in adults) and in humans, are needed. Also, the 
design of new compounds potentiating the stability and bioavailability of the natural 
molecules is an important aim in this topic. Finally, it seems likely that synergistic 
interactions may take place between different phytochemicals and nutrients, so that 
combinations must be developed to find stronger effects than individualized treatments. 
On the other hand, the combination of plant compounds and synthetic drugs might be a 
new therapeutic approach whose study should be encouraged. 
 
4. Epigenetic drugs 
Drugs targeting key enzymes regulating histone modifications and DNA methylation 
(HATs, HDACs and DNMTs) are being extensively studied as anticancer agents. In the 
last years, as several epigenetic mechanisms have been reported to control adipogenic 
differentiation and influence energy metabolism (Kim SJ et al., 2011; Chatterjee et al., 
2011), new interest has been generated about the possible use of epigenetic drugs in the 
treatment of obesity and other metabolic diseases. For example, HDAC9 is 
differentially expressed in subcutaneous and omental adipocytes and functions as a 
negative regulator of adipogenesis (Chatterjee et al., 2011), although in the same 
experiment HDAC inhibitor trichostatin A failed to suppress adipogenic differentiation 
of human subcutaneous preadipocytes. 
Ligation of uterine arteries reduces uteroplacental blood flow and is used to generate a 
model of intrauterine growth retardation (Park et al., 2008). This model has been 
proposed to alter gene regulation patterns due to epigenetic modifications and has been 
linked to the onset of metabolic disease in adulthood, particularly type 2 diabetes in rats. 
Deacetylation of histones H3 and H4 and methylation changes in histone 3 lysine 4 
(H3K4) and histone 3 lysine 9 (H3K9) have been observed in this model. Very 
interestingly, these epigenetic changes could be reversed by HDAC inhibition during 
the neonatal period (Park et al., 2008). 
The repressive actions of the jumonji domain containing 2C/lysine demethylase 4 C 
(JMJD2C/KDM4C) on PPARγ transcriptional activation and in preadipocyte 
differentiation have been recently described. Interestingly, trichostatin A, a HDAC 
inhibitor, was able to reduce the repressive effect of JMJD2C, and also decreased the fat 
storage capacity of the differentiating 3T3-L1 adipocytes (Lizcano et al., 2011). 
In relation to diabetes, several studies have highlighted the beneficial effects of different 
drugs that act through epigenetic mechanisms on restoring insulin secretion (i.e. 3,5-
disubstituted isoxazoles increasing increased the activity of the histone acetyl 
transferase p300 through an ERK1/2-dependent mechanism) (Dioum et al., 2011), or on 
the control of pancreatic β-and δ-cell differentiation (i.e. mutant mice for HDAC4, -5, 
and -9) (Lenoir et al., 2011). In other interesting approach, expression of endogenous 
GLUT4 mRNA in preadipocytes was increased when the levels of class II HDACs in 
the nuclear compartment of 3T3-L1 preadipocytes were reduced using two experimental 
strategies. First, when preadipocytes were treated with phenylephrine, an α-adrenergic 
receptor agonist that drove HDACs out of the nuclear compartment, and secondly when 
class II HDAC concentrations were reduced using siRNA knockdown (Weems and 
Olson, 2011). The oral HDAC inhibitor ITF2357, that reduces production of pro-
inflammatory cytokines in vitro and systemic inflammation in vivo, favors β-cell 
survival during inflammatory conditions in mice with streptozotocin-induced 
hyperglycemia and in vitro (Lewis et al., 2011). In this sense, HDAC inhibitors have 
shown promising anti-inflammatory properties in different animal and cellular models 
of inflammatory diseases and regulate the activity of a wide range of nonhistone 
proteins including NFκB (Christensen et al., 2011). Moreover, inhibition of various 
HDACs (HDAC1, -2, -4 and -5) appears to be a promising novel therapeutic principle 
to correct the insulin-resistant state, as HDACs play a regulatory role in physiological 
insulin signaling by increasing GLUT4 translocation and augmenting basal and insulin-
induced glucose uptake in skeletal muscle (Takigawa-Imamura et al., 2003), but also by 
promoting differentiation of embryonic stem cells into insulin-producing cells 
(Tarayamma et al., 2006). 
However, there is a lack of clinical studies and much concern must be given to the 
secondary effects that these epigenetic drugs could cause in the different tissues. 
 
5. Obesity-related physiological factors 
5.1. Inflammation 
An increasing number of experimental and epidemiological evidences link complex 
diseases, such as obesity, type 2 diabetes, cardiovascular diseases, asthma, allergy, and 
several types of cancer, with chronic inflammation. In the case of obesity and type 2 
diabetes, all major risk factors (overnutrition, low dietary fiber, sedentary lifestyle, 
stress, sleep deprivation and depression) have been found to induce local or systemic 
low-grade inflammation (Solinas and Karin, 2010). In fact, it has been suggested that 
chronic low-grade inflammation eventually leads to overt diabetes when counter-
regulatory circuits to inflammation and metabolic stress are compromised because of 
genetic or epigenetic predisposition (Kolb and Mandrup-Poulsen, 2010). 
The inflammatory response is very complex and requires the precise control of many 
functional mechanisms operating at different levels, such as the presence of different 
types of immune cells in the tissue, the responsiveness of different signaling pathways 
to the inflammatory stimuli and also the regulation of gene expression by epigenetic 
modifications (Medzhitov and Hong, 2009). Recent therapeutic interventions using 
HDAC and DNMT inhibitors (Altucci and Stunnenberg, 2009) as well as increasing 
data demonstrating the effect of certain anti-inflammatory dietary elements on DNA 
methylation or chromatin remodeling (vel Szic et al., 2010) highlight the connection 
between inflammation, non-communicable diseases and epigenetics. 
5.1.1. Participation of immune cells 
Immune cell specific mechanisms operate at the level of different tissues and include 
regulation of their recruitment and activation. Acute inflammation is mediated by 
granulocytes or polymorphonuclear leucocytes, while chronic inflammation is mediated 
by mononuclear cells such as monocytes and macrophages that produce pro-
inflammatory cytokines, ROS and NOS. These cells can be further stimulated to 
maintain inflammation through the action of an adaptive cascade involving T, B and 
dendritic cells. (vel Szic et al., 2010). As a consequence, in chronic inflammatory 
diseases there is a distortion in the extent of the inflammatory response, in the sense that 
it cannot be reset again. Genetic and non-genetic (environmental or epigenetic) factors 
are behind these differences (Bäckdahla et al., 2009). For instance, Th1 cells have been 
associated with chronic inflammatory diseases and activate macrophages, while Th2 
have the opposite effect and induce antibody production. A specific Th lineage that 
produces IL17 (Th17) has been also pointed as a strong mediator of inflammation and 
development of chronic inflammatory diseases. Th17 differentiation is dependent on 
epigenetic modifications like the histone acetylation and H3K4me3 of the IL17 
promoter (Akimzhanov et al., 2007). 
5.1.2. Transcription Factors 
Transcription factors (NFkB, IRF, CREB) constitutively expressed in many cell types 
are responsible for the integration of signals from different pathways and are in charge 
of the primary response to inflammation, triggering the initial phase of gene induction. 
Other factors require de novo synthesis following inflammatory stimulation (C/EBPd) 
or are expressed in a cell type or differentiation specific manner (Runx, PU.1, IRF8, 
C/EBP) establishing a particular pattern of gene expression by epigenetic mechanisms 
such as chromatin remodeling. All these transcription factors do not act independently 
but function coordinately to control the inflammatory transcriptional response, defining 
clusters of genes that are regulated in a coordinate manner (Medzhitov and Hong, 2009; 
Ramirez-Carrozi et al., 2009). In chronic tissue-specific inflammatory diseases there is a 
downregulation of the anti-inflammatory responses together with the upregulation of the 
proinflammatory ones exerted at specific sites by transcription factors and another DNA 
binding proteins. 
For an efficient interaction with DNA, transcription factors need to cooperate with 
chromatin remodeling factors (DNMTs, histone methylases and demethylases, HATS 
and HDACs etc.). Multiple post-translational modifications (methylation, acetylation, 
phosphorylation, ribosylation, sumoylation, ubiquitination) of these proteins and 
cofactors allow a very dynamic interaction among them in order to integrate 
epigenetically a variety of different environmental inputs that will determine the 
adjusted expression of inflammatory genes (Perissi et al., 2010; Dong et al., 2008). 
Some primary response inflammatory loci may not require chromatin remodeling 
activity for activation, since their promoters contain CpG islands that fall into 
constitutively active regions assembled in unstable nucleosomes. Others, on the 
contrary, fall in heterochromatic regions and bear fairly stable nucleosomes, requiring 
the participation of chromatin remodeling complexes for active transcription (Ramirez-
Carrozzi et al., 2009). 
NFκB is a key factor of the proinflammatory immune response. It regulates the 
expression of hundreds of genes including many mediators that amplify the 
inflammatory response aggravating the disease status (Olefsky, 2009). Different 
members of the NFκB family work in concert with other transcription enhancer factors 
such as CREB, C/EBP, AP1, NFAT, SP1, STAT etc. (O’Dea and Hofmann, 2010) 
modulating a tailored response with the participation of HATs and HDACs (Werner et 
al., 2005) which can finally regulate the epigenetic modification not only of the NFκB 
target genes (Vanden Berghe et al., 2006). 
5.1.3. Inflammation, oxidative stress and hypoxia 
In inflammatory processes, the release of reactive oxygen and nitrogen species (ROS 
and RNS) mainly by neutrophils and macrophages leads to oxidative stress and tissue 
damage, which can inhibit HDACs thereby activating silenced genes. Likewise, ROS 
production also leads to the activation of signaling cascades such as ERKs, which in 
turn induce NFκB immune response provoking changes in histone 
acetylation/deacetylation that finally result in altered transcription initiation (Adler et 
al., 1999). An increase in proinflammatory cytokines that contributes to the chronicity 
comes as a consequence of these ROS mediated mechanisms. 
Inflammation can induce a certain level of hypoxia which in turn can reinforce the 
inflammatory state essentially by the HIF-1 capacity of attracting macrophages that 
would increase the array of proinflammatory mediators (MIF, TNF, IL-6, IL-10) (Shah 
et al., 2008). HIF-1 can also affect histone code through HDAC2 inhibition (Charron et 
al., 2009) and the direct induction of H3K9 demethylases expression (Pollard et al., 
2008). This would favor a less compacted state that will make DNA more susceptible to 
damaging agents generated during chronic inflammation. At the same time a possible 
epigenetic mechanism is depicted whereby HIF-1-mediated induction of histone 
demethylases would favor the removal of H3K9 methyl marks, the loosening of 
chromatin compaction and the exposure to transcription of otherwise silent genes 
(Brigati et al., 2010). This increase of demethylases activity could rapidly spread and 
boost the number of derepressed genes (Talbert and Henikoff, 2006). 
5.1.4. Environmental influence 
Environmental conditions are also crucial for understanding the epigenetics of 
inflammation, where a whole array of molecular influences could take part in the 
modification of the histone code. This emphasizes the importance of diet and lifestyle in 
the shaping of a changing epigenome. Furthermore, increasing evidence indicates that 
these environmental influences are also critical transgenerationally impacting 
gametogenesis and embryogenesis. 
As an example, after a transient glucose level increase NFκB transcriptional activity is 
enhanced and maintained high through H3K9 demethylation of its promoter (El Osta et 
al., 2008; Brasacchio et al., 2009). On the other hand, lifestyle factors known to 
promote type 2 diabetes are associated with a local and/or systemic inflammatory 
reaction. Likewise, high glucose levels increase mitochondrial and respiratory activity 
and give rise to enhanced release of superoxide anions (El Osta et al., 2008). This 
oxidative stress induces the expression of pro-inflammatory cytokines, such as IL-6 and 
TNF-α, through signaling cascades involving JNK, MAP-kinases, and transcription 
factors, such as NFκB and AP-1 (Kempf et al., 2007). The cell response varies 
depending on the tissue affected and may include ectopic fat storage, mitochondrial 
dysfunction and endoplasmic reticulum stress, but the inflammatory response is usually 
self-limiting. However with increased exposure to pro-inflammatory challenges, the 
counter-regulatory anti-inflammatory feedback inhibition mechanisms may start to fail 
and chronic inflammation ensues in those genetically predisposed ending up in diabetes. 
In this regard, a dysfunction of neural regulatory systems such as leptin resistance, 
which is also associated to type 2 diabetes, has been closely linked with local 
inflammation (Velloso et al., 2008). 
Accordingly, persons with type 2 diabetes, metabolic syndrome or obesity exhibit more 
pronounced and longer-lasting inflammatory responses to a challenge than 
metabolically normal controls in most studies. The endoplasmic reticulum is involved in 
most metabolic routes and has become a key cellular structure in the adaptive response 
to nutritional changes, such as those accompanying obesity (hyperglycemia, fatty acid 
overload). When the challenge overcomes endoplasmic reticulum response capacity, the 
unfolded protein response comes into place involving many inflammation and stress 
signaling pathways related with chronic inflammatory diseases (Hotamisligil 2010; 
Mandl et al., 2009). Some of the deleterious effects of endoplasmic reticulum have been 
restored by the treatment with HDAC inhibitors, such as trichostatin A (Kimura et al. 
2012). 
Apart from high glucose concentrations, excess of saturated fatty acids induce oxidative 
stress with NAD(P)H oxidase activation, ROS production and endoplasmic reticulum 
stress, which lead to transcriptional activation of proinflammatory cytokines (IL-1, IL-6, 
TNF-α) through the activation of NFκB, AP-1 or CREB (Schenk et al., 2008; Milansky 
et al., 2009). TLR4 receptor mediates the pro-inflammatory effects of saturated fatty 
acids and also of high glucose concentrations, both of which might result in a sustained 
chronic inflammatory process without a balanced regulatory feedback (Milansky et al., 
2009). 
5.1.5. Epigenetic modifications 
The epigenetic code involved in gene expression regulation is modified during chronic 
inflammation. Thus, agents produced by oxidative stress, such as ROS and RNS, cause 
loss of DNA methylation after mitosis, since DNMT1 does not recognize oxidized 
methyl groups, whereas halogen derivatives produced by inflammatory processes mimic 
cytosine methylation producing a gain of methylation by DNMT1 (Valinluck and 
Sowers, 2007). In a complex regulatory network, the expression of cytokines, such as 
TNF-α, is tightly regulated by epigenetic mechanisms (Sullivan et al., 2007), but 
cytokines, such as IL-6, regulate other genes and processes by inducing histone 
modifications and DNA methylation (Wehbe et al., 2006). 
Additionally, the administration of a range of HDAC inhibitors has been reported to 
suppress the expression of proinflammatory cytokines in experimental models of 
inflammatory diseases (Lin et al., 2007). In this sense, chronic inflammation seems to 
promote a transcriptional repressive state since the HDAC inhibitors block enzymes that 
silence transcription. Inhibition of both HDACs and DNMT1 are of therapeutic benefit 
in chronic inflammation and both types of enzymes integrate a transcriptional repression 
complex interacting through the methyl binding protein MeCP2 (Jones et al., 1998). In 
another report studying histone methylation inhibition during the inflammatory response 
induced by LPS, it was demonstrated that the H3K27me3 demethylase (Jmjd3) is 
directly regulated by NFκB (De Santa et al., 2007). Essentially, tissue-specific chronic 
inflammation is characterized by an epigenetic state with enrichment of hypo-acetylated 
histones and hyper-methylated CpGs that contribute to a persistent inflammatory 
response. 
5.1.6. Future perspectives 
A better understanding of the epigenetic consequences of chronic inflammation in 
metabolic diseases will open the possibility for prevention but also for therapeutic 
actions, since the reversible nature of these processes foresees a great potential for the 
treatment, stabilization and even recovery of these disorders. In obese persons at risk of 
developing type 2 diabetes, besides implementing a healthy lifestyle and calorie 
restriction, a logical approach would be to aim at re-establishing the mechanisms 
underlying the self-limiting of inflammatory responses (Kolb and Mandrup-Poulsen, 
2010). The possibility of modulating the methylation status of critical inflammatory 
genes by dietary interventions with a variety of different natural products is receiving 
much attention, as a mean to protect or ameliorate inflammatory diseases. However 
there is concern about the possibility that the use of inhibitors or activators of epigenetic 
enzymes (DNMT, histone methylases, histone demethylases, HAT, HDAC) would lack 
enough specificity, especially in long term treatments. 
It will be also necessary to search for novel epigenetic targets aiming at the selective 
modulation of the inflammatory signaling network in the affected organs, in order to 
broaden the possibilities of anti-inflammatory therapeutic intervention. In this regard 
microRNAs and long ncRNAs are arising as very promising candidates especially 
because they show a clear target sequence specificity that could represent the direct 
connection between the genome and the epigenome. 
 
5.2. Oxidative stress 
Excessive oxidative stress results from an imbalance between tissue oxidants (free 
radicals or reactive oxygen species (ROS)) and antioxidants that is usually exacerbated 
in the different tissues of obese subjects, including plasma (Urakawa et al., 2003), liver 
(Milagro et al., 2006) and adipose tissue (Furukawa et al., 2004). This oxidative stress 
triggers the development of insulin resistance and is responsible of some of the 
comorbidities that accompany obesity (Urakawa et al., 2003, Vincent and Taylor, 
2006), including the inhibition of preadipocyte differentiation that may contribute to 
age-associated adipose tissue dysfunction (Findeisen et al., 2011). In addition, animal 
studies show that oxidative stress in adipose tissue contributes to dysregulation of 
adipokine production via PPARγ-responsive element in the adiponectin gene promoter 
and to obesity (Furukawa et al., 2004; Houstis et al., 2006). The main strategies that 
have been implemented in the reduction of obesity-related oxidative stress are weight 
loss and antioxidant supplementation. Weight loss reduces enhanced oxidative stress 
and different methods, such as physical activity, caloric restriction, and surgical 
intervention, have been proposed to combat free radicals and reduce adipose tissue 
(Vincent and Taylor, 2006). Regarding antioxidant supplementation, Yeon et al. (2011) 
have shown that the plasma total antioxidant capacity significantly increases as the 
quartile value of dietary fiber and antioxidant vitamins, such as vitamin A, β-carotene, 
vitamin C, and vitamin E increases, whereas 8-OHdG level is negatively associated 
with vitamin A and β-carotene intake. Both mechanisms (weight loss and dietary 
antioxidants) have been reported to induce changes in epigenetic marks (Bouchard et 
al., 2010; Chung et al., 2010). 
Oxidative DNA damage may induce DNA structure and base modifications, such as 
deletions, strand breakage, and chromosomal rearrangements (Valko et al., 2006). 
Replacement of guanine to 8-hydroxy 2'-deoxy-guanosine (8-OHdG), one of the major 
DNA oxidative damage by-products, substantially diminishes the binding of methyl-
CpG binding proteins (important to manage site-specific chromatin organization and 
transcriptional repression) and results in heritable epigenetic changes (Valinluck et al., 
2004). In addition, some DNA lesions have been shown to interfere with the ability of 
DNA to function as a substrate for the DNA methyl transferases (DNMTs), resulting in 
global hypomethylation (Zhang et al., 2007). Thus, increased DNA damage and 
chromosomal degradation could be associated with alterations of either 
hypermethylation or hypomethylation of the DNA (Lim et al., 2008). There are studies 
reporting that ROS interact with histone deacetylases and DNA methyltransferases and 
can stimulate the methylation of specific promoters, such as E-cadherin, a gene involved 
in cell adhesion (Lim et al., 2008), or the extracellular superoxide dismutase SOD3 
(Zelko et al., 2011). 
With these encouraging precedents, more research is needed in the field of epigenetics 
and antioxidant compounds in relation to obesity and type 2 diabetes, including the 
study of the interactions with other nutritional factors and the genetic background. 
 
 
5.3. Hypoxia 
Obesity is characterized by hypertrophy and hyperplasia of adipocytes (Spalding et al., 
2008). This excessive fat deposition in adipose tissue is limited, being the diffusion 
limit of oxygen considered one of the main reasons. Hypoxia occurs when oxygen 
availability does not match the demand of the surrounding tissue, resulting in decreased 
oxygen tension. Hypoxic stress plays a pivotal role in normal human development and 
physiology, including embryogenesis and wound repair, and has been well studied for 
its importance in the pathogenesis of several human diseases, including heart disease, 
stroke, diabetes, and cancer (Gore et al., 2010). In adipose tissue of obese mice there is 
evidence for hypoxia, which elicits dysregulated production of adipocytokines and 
downregulates adiponectin expression by mediation of endoplasmic reticulum stress-
dependent transcriptional and -independent posttranscriptional mechanisms (Hosogai et 
al., 2007). Therefore, local hypoxia in adipose tissue may provide cellular mechanisms 
for chronic inflammation, macrophage infiltration, adiponectin reduction, leptin 
elevation, adipocyte death, endoplasmic reticulum stress and mitochondrial dysfunction 
in obesity. The concept suggests that inhibition of adipogenesis and triglyceride 
synthesis by hypoxia may be a new mechanism for elevated free fatty acids in the 
circulation in obesity (Hosogai et al., 2007; Woods et al., 2009). 
Hypoxia in general decreases global transcriptional activity, in part, through epigenetic 
regulation. Thus, a global decrease in H3K9 acetylation is a possible consequence of 
hypoxia-induced HDAC upregulation (Johnson et al., 2008). In fact, the H3K9 
acetylation reduction occurs by the increase G9a histone methyltransferase expression, 
which raises global H3K9 methylation, a repressive histone mark (Chen et al., 2006). 
Changes in DNA methylation have been also associated with hypoxic conditions, 
including loss of global methylation in colorectal and melanoma cancer cell lines 
(Shahrzad et al., 2007). A recent example by Nanduri et al. (2012) describes that 
intermittent hypoxia exposure in neonatal rats causes an exaggerated response to 
hypoxia associated with increased oxidative stress. In this animal model, 
hypermethylation of a single CpG dinucleotide close to the transcription start site of 
superoxide dismutase 2 seems to regulate SOD2 gene expression. Although these 
findings are preliminary, the observed epigenetic modifications occurred in transcribed 
genomic regions in obesity by hypoxia. 
A key regulator of the adaptive response to alterations in oxygen tension is hypoxia-
inducible factor-1 (HIF1), a transcription factor that accumulates during hypoxia and 
increases the expression of a wide variety of genes that stimulate erythropoiesis, 
angiogenesis, and glycolysis (Singh et al., 2012). This transcription factor may 
influence gene expression at the level of histone modifications. Thus, HIF-1α binds to 
specific recognition sites in the genes encoding the jumonji family histone demethylases 
JMJD1A and JMJD2B and induces their expression in hypoxic conditions (Beyer et al., 
2008). Genomic DNA methylation is also regulated by activation of HIF-1α through the 
up-regulation of methionine adenosyltransferase II alpha (MAT2a) in hepatoma cells 
under hypoxic conditions (Liu et al., 2011). This study revealed a positive correlation 
between HIF-1α and MAT2a promoter activity expression in Hep3B cells after hypoxic 
treatment, and the use of siRNA to knockdown HIF-1α prevented the expression of 
MAT2a.  Furthermore, ChIP analysis detected a significant increase in the binding of 
HIF-1α to the MAT2a promoter within hypoxic Hep3B cells. On the other hand, histone 
deacetylase inhibitors have been employed to disrupt the function of hypoxia-inducible 
factors in cancer and chronic ischemic disorders (Chen and Sang, 2011). For the 
moment, no results have been reported in the treatment of metabolic disorders. 
Both hypoxia and hyperoxia have been proposed as an alternative treatment for weight 
loss treatment (Quintero et al., 2010). For example, when studying the reasons for 
weight loss at high altitudes, higher metabolic rate and reduced food intake have been 
described, although the physiological mechanisms remain unclear (Lippl et al., 2010). 
The implementation of these potential therapies are subject to different genetic and 
environmental factors that must be clarified, including oxygen concentration, time of 
exposure, acclimation time, physical activity and dietary nutrient composition, some of 
which probably act by epigenetic mechanisms. 
 
5.4. Hyperglycemia 
Obese individuals are at a significantly greater risk for hyperglycemia than those who 
are nonobese, irrespective of their age (Wakabayashi et al., 2012). In fact, obesity is 
considered an important contributor to the impairment of insulin signaling in the 
peripheral tissues and type 2 diabetes development. In this sense, a recent article has 
evidenced the role of epigenetics in the pathogenesis of type 2 diabetes, finding 276 
CpG loci affiliated to 254 gene promoters displaying significant differential DNA 
methylation in diabetic pancreatic islets (Volkmar et al., 2012). 
Glucose is considered one of the main metabolic factors that epigenetically regulate 
gene expression. Thus, glucose modulates the transcription of the insulin gene by 
hyperacetylation of histone H4 (Mosley and Ozcan, 2003). In fact, the histone 
acetyltransferase p300 is recruited to the insulin promoter only at high concentrations of 
glucose via its interaction with the beta-cell-specific transcription factor Pdx-1 (Mosley 
et al., 2004). Another interesting report has shown that glucose regulates acetylation and 
methylation of various histone residues at the gene promoter of L-type pyruvate kinase, 
the rate-limiting step of the glycolytic pathway (Burke et al., 2009). 
In the last years, several studies have analyzed the relationship between poor glycemic 
control in diabetic patients and epigenetic alterations that could be involved in the 
comorbidities associated to this disease. Thus, poor glycemic control mediates post-
translational modifications to the H3 histone tail and, by using ChIP-seq and CpG-seq, 
it has been shown that hyperglycemia-mediated induction of genes associated with 
endothelial dysfunction occurs through modulation of acetylated H3K9/K14 and is 
inversely correlated with methyl-CpG content (Pirola et al., 2011). 
Transient episodes of hyperglycemia can induce changes in gene expression that are 
dependent on histone tails modification and these changes persist after return to 
normoglycemia (Tonna et al., 2010). Some of these changes have been found in the 
promoter of the nuclear factor κB (NFκB) subunit p65 in aortic endothelial cells both in 
vitro and in nondiabetic mice, and are a cause of long-lasting increase in p65 gene 
expression (El-Osta et al., 2008). The phenomenon by which diabetes complications 
persist and progress after glycemic recovery is achieved is called metabolic memory. 
Interestingly, a recent report has demonstrated that metabolic memory is heritable and 
its transmission correlates with hyperglycemia-induced DNA hypomethylation and 
aberrant gene expression in streptozotocin-induced hyperglycemic zebrafish (Olsen et 
al., 2012). The daughter tissue, which was never exposed to hyperglycemia but was 
derived from tissue that was, does not exhibited higher levels of advanced glycation 
endproducts (AGEs) and oxidative stress, but hyperglycemia-induced global DNA 
hypomethylation persisted and was correlated with aberrant gene expression for a subset 
of loci in this daughter tissue (Olsen et al., 2012). To summarize, environmental factors, 
including the diet and episodes of transient hyperglycemia, contribute to the etiology 
and the microvascular and macrovascular complications of diabetes mellitus by 
generating long-lasting epigenetic modifications that lead to changes in chromatin 
structure and gene expression (Pirola et al., 2010). 
According to this hypothesis, obese individuals are more prone to suffer episodes of 
transient hyperglycemia. Even if these individuals return to normal glycemic control, 
hyperglycemia may induce long lasting effects by producing alterations in epigenetic 
processes and marks that facilitate the development and progression of metabolic 
complications (Siebel et al., 2010). Obviously, although it has not yet been studied in 
depth, genetic sequence, hormones, oxidative stress, inflammation and other 
environmental factors should play a role in the regulation of metabolic memory. Hence, 
two top priority objectives in this field are: 1) to early detect those individuals with 
more hyperglycemia-induced epigenetic alterations in order to prevent the future 
development of diabetic complications; and 2) to find new therapeutic agents that could 
slow down or stop the degenerative process by epigenetic mechanisms.  
 
5.5. Circadian rhythms and sleep 
Sleep duration has declined from 8-9 h per night to 7 h or less in the last 50 years, 
largely as a consequence of voluntary sleep restriction (McAllister et al., 2009). Sleep 
debt has been associated with decreased insulin response and glucose effectiveness, 
impaired glucose regulation by reduced lipolytic effects and increased sympathetic 
nervous system activity (Spiegel et al., 2009). During sleep restriction, plasma leptin 
levels are decreased, whereas ghrelin, cortisol and orexin secretion is increased, which 
has been associated with an increase of food intake and obesity incidence (Bo et al., 
2011). 
Apart from sleep deprivation, bright light exposure at night, shift work and nocturnal 
eating are frequent situations in obesity (Garaulet et al., 2010) that could influence the 
methylation levels of clock genes and other epigenetic mechanisms. Thus, shiftwork 
exposure induces alterations in blood DNA methylation, including gene-specific 
methylation of IFN-γ and TNF-α promoters (Bollati et al., 2010). Melatonin, the major 
hormonal regulator of circadian rhythm, is able to modulate histone acetylation and 
DNA methylation (Korkmaz et al., 2009) and may influence diabetes by inhibiting 
insulin secretion, but also by protecting pancreatic β-cells from reactive oxygen species 
(Peschke and Mühlbauer, 2010). Hence, the involvement of epigenetic mechanisms in 
the melatonin-dependent synchronization of circadian insulin secretion to day/night 
changes must be envisaged. 
Rhythmic changes in histone acetylation at circadian clock genes regulate the temporal 
modulation of gene expression by modifying chromatin. In this sense, a seminal study 
of Alenghat et al. (Alenghat et al., 2008) suggested that circadian regulation of 
metabolism is critical for normal energy balance. In this article, genetic disruption of the 
interaction between the histone deacetylase 3 (HDAC3) and its activator nuclear 
receptor corepressor 1 (Ncor1) altered the oscillatory patterns of several metabolic 
genes and resulted in leaner mice with more insulin-sensitivity owing to increased 
energy expenditure. 
CLOCK gene is the first essential component of the mammalian clock. It is a histone 
acetyltransferase that contributes to the time-dependent regulation of circadian 
physiology by acetylating its own partner BMAL1 (Hirayama et al., 2007). In this 
sense, alterations in clock gene methylation have been detected in different diseases like 
Parkinson (Lin et al., 2012), whereas DNA hypermethylation-associated loss of 
BMAL1, which has been reported in leukemia/lymphoma cells, prevents the 
recruitment of its natural partner, CLOCK, to their common targets, further enhancing 
the perturbed circadian rhythm of the cancer cells (Taniguchi et al., 2009). Very 
importantly, a maternal diet rich in fat modulates in utero the acetylation of fetal histone 
H3 at lysine 14 (H3K14ac) in NPAS2, a paralog of the CLOCK transcription factor, 
affecting thus the peripheral circadian system of the fetus (Suter et al., 2011). This result 
invites investigation on the different factors (nutritional or environmental) that could 
affect the epigenetic regulation of clock genes in various organs, both in fetal and adult 
life. Apart from animal studies, the epigenome of people working in shifts, at night or 
with irregular work hours, or the comparison of people with morning or evening 
preference could be of interest in the development of personalized nutrition for combat 
obesity and its comorbidities.  
 
5.6. Ambient temperature 
Indoor heating during cold seasons and air conditioning during warm seasons may 
contribute to rising obesity because the body expends less energy in temperature ranges 
associated with climate-controlled settings (Bo et al., 2011). Brown adipose tissue 
(BAT) is an important contributor to heat production in response to cold, and obese 
individuals seem to have less BAT mass and activity than normal weight subjects 
(Ravussin and Galgani, 2011). In this sense, it has been reported that mice knockout for 
the histone H3k9-specific demethylase Jhdma2a have reduced amount of BAT and 
increased body weight after 8 weeks of age (Inagaki et al., 2009; Tateishi et al., 2009). 
They are also more susceptible to cold-induced hypothermia and less able to oxidize fat 
primarily due to a disruption of β-adrenergic stimulation. The expression of UCP1, the 
main protein regulating thermogenesis in BAT, seems to be mediated by epigenetic 
mechanisms. Thus, demethylation of the UCP1 promoter by 5-aza-deoxycytidine 
increases UCP1 expression in adipose cell lines while methylation of UCP1 promoter-
reporter constructs decreases the expression, which demonstrates a role for CpG 
methylation in the control of UCP1 transcription. Unfortunately, no differences in 
UCP1 promoter methylation have been found when comparing BAT of mice exposed or 
not to a cold environment (Shore et al., 2010). The authors suggest that increasing the 
expression of UCP1 by epigenetic mechanisms could be a potential treatment for 
obesity. It is also likely that the emergence of cold-induced brown adipocytes in mouse 
white adipose tissue is determined predominantly by white to brown adipocyte 
transdifferentiation, which could involve epigenetic mechanisms mediated or not by β3-
adrenoceptors (Barbatelli et al., 2010). 
 
5.7. Psychological stress 
In modern societies, mental and psychosocial stress has become a typical trait that 
involves chronic activation of the neuroendocrine systems, which has been linked to the 
increased prevalence of obesity (Siervo et al., 2009). For instance, in a recent report, 
major life events and vital exhaustion have been associated with weight gain and risk of 
obesity (Iversen et al., 2012). 
Although few epigenetics studies have been performed in adult population, maternal 
and early life stress have been extensively analyzed and, in all cases, strong epigenetic 
modifications have been found in the offspring that, in many cases, remain until adult 
life. In this sense, it is clear that maternal stressors, including hypoxia and protein or 
calorie restriction, result in cellular and hormonal damage and affect epigenetic 
responses in the placenta, compromising placenta functions and leading to long-term 
consequences for fetal development (Gheorghe et al., 2010). Perinatal undernutrition is 
one of these stressors. This nutritional stress has been reported to remove methyls at 
CpGs located in leptin promoter that persists throughout life and is associated with 
lower levels of leptin mRNA and an imbalance between food intake and energy 
expenditure in adults (Jousse et al., 2011). Maternal constraint is other of these 
stressors. First-born children experience a greater degree of maternal constraint during 
gestation and, as adults, they often show higher adiposity and visceral obesity than their 
younger siblings (Reynolds et al., 2010). Epigenetic processes could partially explain 
these data because they are involved in matching fetal growth to mother’s complexion, 
body composition and lifestyle (Hanson et al., 2011b). 
Stress at early ages is also clearly associated to hormonal alterations and epigenetic 
modifications. Thus, differences in histone acetylation and in DNA methylation of 
glucocorticoid receptor in the hippocampus have been found when comparing the 
offspring of rat mothers that showed high and low levels of pup licking and grooming 
and arched-back nursing (Weaver et al., 2004). These differences emerged over the first 
week of life but persisted into adulthood. In humans, maternal touch and feed are 
considered also critical regulators of behavioral and stress responses in the offspring 
(Walker et al., 2010), although its importance as an obesity risk factor and the alteration 
of epigenetic processes have never been analyzed. However, it has been observed that 
childhood abuse, neglect and loss induce alterations of the epigenetic mechanisms 
(McGowan et al., 2009). They are major risk factor for developing depressive disorders 
later in life (Heim and Binder, 2012) and could be related with epigenetic mechanisms 
and chronic alterations in cortisol secretion in children that could affect body 
composition and be causative factors of early-onset obesity, metabolic syndrome, and 
type 2 diabetes (Pervanidou and Chrousos, 2011). 
Although epidemiological data suggest that psychological stress could act also as a 
causative factor of obesity in adults, there are many confusing factors that must be 
carefully studied and the etiological mechanisms remain unclear (Tamashiro et al., 
2011). However, there are suggestive precedents indicating that mice living in an 
enriched environment with complex physical and social stimulation leads not only to 
improved cognitive and metabolic health, but also to a switch of white to brown fat 
phenotype and the expression of genes involved in thermogenesis associated with 
resistance to diet-induced obesity (Cao et al., 2011). Epigenetics could be behind some 
of these observations but new ad hoc studies must be carried out. Moreover, as 
maturation rates and the extent of plasticity across development are highly variable for 
different brain regions and for the different tissues, timing of the stressor events is a 
critical factor and it is important to identify the most sensitive periods (Heim et al., 
2012). 
 
5.8. Socioeconomic status 
In countries with a higher gross domestic product, but not in most developing countries, 
lower income inequality is one of the strongest determinants to develop overweight, 
obesity and cardiovascular diseases (Jones-Smith et al., 2011). It has been usually 
explained by decreased physical activity, unhealthy behaviors and cultural and social 
barriers (Voorhees et al., 2009) but, in the last years, psychological and sociological 
biological determinants have been reported to be associated with epigenetic 
mechanisms. Thus, in the pSoBid cohort, which is characterized by an extreme socio-
economic and health gradient, global DNA hypomethylation was observed in the most 
socio-economically deprived subjects and was also associated with biomarkers of 
cardiovascular disease and inflammation (McGuinness et al., 2012). Also, microarray 
analyses carried out in males of the British Birth Cohort Study show that adult blood 
DNA methylation profiles is associated with disadvantaged socio-economic status, 
especially with that of childhood (Borghol et al., 2011). These results strongly support 
the hypothesis that low early-life social class is a key factor in enduring differences in 
adult expression of genes critical for human health by leaving their mark on the 
epigenome. Anyway, more studies are needed in order to know the specific factors with 
the most impact in epigenetic changes induced by the socioeconomic status, with 
perinatal and early life nutrition and stress being some of the most likely candidates. 
 
5.9. Hormonal and neuropeptide imbalance 
The onset of obesity and insulin resistance is sometimes associated with hormonal 
imbalances. Also, fat distribution in visceral and subcutaneous depots is regulated by 
the secretion of different hormones including cortisol, insulin, adiponectin, leptin, 
estrogens, dihydrotestosterone and growth hormone (Mattson and Olsson, 2007). 
Although the direct effects of these hormones on fat deposition and insulin signaling are 
well established, some of them have been reported to induce epigenetic modifications. 
For instance, whereas 17β-estradiol hypermethylates O6-methylguanidine-DNA in lung 
cancer cells (Lai et al., 2009), insulin induces global hypomethylation in HepG2 liver 
cells in culture (Chiang et al., 2009) and reduces the methylation level at H3R17, 
downregulating PEPCK and G6Pase, the rate-determining enzymes of gluconeogenesis 
(Hall et al., 2007). Leptin, a key gene in energy balance regulation, is hypomethylated 
in whole blood of humans being born small for gestational age due to prenatal growth 
restriction early in pregnancy (Tobi et al., 2011). Glucocorticoids, which affect food 
intake and abdominal obesity, cause local DNA demethylation of the tyrosine 
aminotransferase gene around a glucocorticoid response element that appears to 
contribute to the memorization of long-term effects of glucocorticoids in neonatal brains 
(Thomassin et al., 2001). According to these encouraging data, more emphasis must be 
made in the study of the epigenetic alterations due to transient or chronic hormonal 
imbalances, which are so common in obesity and related comorbidities, as well as in the 
knowledge of the epigenetic mechanisms that regulate the secretion of hormones as a 
result of dietary and environmental factors. 
Appetite regulation involves a complex interplay of hunger and satiety signals that is 
based in the hypothalamus. Some of these signals consist of orexigenic and 
anorexigenic neuropeptides, such as POMC, MC4R, NPY and CART, some of which 
have been reported to be regulated epigenetically. Thus, periconceptional undernutrition 
induces proopiomelanocortin (POMC) promoter hypomethylation in the hypothalamus 
of sheep (Stevens et al., 2010), and is also associated with reduced DNA 
methyltransferase activity and altered histone methylation and acetylation (Begum et al., 
2012). On the other hand, when suffering early overfeeding, the hypothalamic POMC 
promoter becomes hypermethylated (Plagemann et al., 2009). Neuropeptide Y (NPY), 
one of the main appetite-inducing factors, was one of the ten CpG sites that were 
hypermethylated in mucosa from colorectal cancer patients when compared to normal 
mucosa (Kim YH et al., 2011), and is also frequently hypermethylated in hepatocellular 
carcinoma tissue samples (Shin et al., 2010). In this sense, it is crucial to understand the 
epigenetic mechanisms involved in the regulation of these genes in the hypothalamus in 
response to different hormonal, dietary and environmental factors in order to understand 
physiological and pathological aspects of appetite regulation that could provide 
potential targets for the treatment of obesity. In particular, more emphasis must be made 
in maternal nutrition, which modifies, in some cases through epigenetic mechanisms, 
metabolic or endocrine signals acting on genes encoding neuropeptides. 
 
5.10. Endocrine disruptors and toxics 
Environmental endocrine disruptors are synthetic chemicals that resemble natural 
hormones and are known to cause epigenetic perturbations and profound effects on 
development and fertility (Kang et al., 2011). Endocrine disrupting chemicals like 
tributyltin interfere with the adipose tissue biology, endocrine hormone systems and 
hypothalamic-pituitary-adrenal axis and deregulate the homeostatic mechanisms that 
control weight (Grün and Blumberg, 2010). There is evidence that early life exposure 
(pre- or early postnatally) to endocrine-disrupting chemicals may be a risk factor for 
obesity and related metabolic diseases later in life (Miyawaki et al., 2007). Polluting 
chemical substances which may potentially induce obesity in humans are organotins 
(TBT, TPT) and phthalates, which act as PPARγ activators, but also diethylsylbestrol 
(DES), genistein and bisphenol A, three substances mainly acting upon estrogen 
receptors (Newbold, 2010). During this period of life, and more specifically during 
embryonic gonadal sex determination, chemicals can exert effects at very low levels of 
exposure and may involve epigenetic events that could be transgenerationally 
transmitted (Anway et al., 2005). Hence, some research projects are studying the effects 
of these chemicals on obesity development, such as OBELIX (Legler et al., 2011), and 
will include epigenetic analyses in both animal models and children. 
There are examples in which vinclozolin, an endocrine disruptor with antiandrogenic 
effects, or bisphenol A modulate the monoallelic expression of imprinted genes (Kang 
et al., 2011), and can alter the male germ-line DNA methylation, transmitting thus 
transgenerational adult onset disease (Anway and Skinner, 2008). In some cases, these 
alterations have been observed in the sperm of F3 generation rats whose F0 generation 
mother was exposed to vinclozolin (Guerrero-Bosagna et al., 2010). In this sense, 
endocrine disruptors act by inducing epigenetic alterations in estrogen responsive 
elements (ERE) sensitivity to estrogens (Bromer et al., 2010). As it is well established 
that early exposure to bisphenol A leads to adult obesity (Rubin, 2011), and that this 
compound induces profound alterations in DNA methylation and other epigenetic 
processes, it is necessary to design new perinatal and transgenerational experiments in 
rodents that could determine the targets and periods of life that are more sensitive to 
these endocrine disruptors, as well as the doses. 
Even in the adult age, toxins are able to alter the epigenome. In this sense, particulate air 
pollution has been associated with increased cardiovascular events, and lower blood 
DNA methylation has been found in processes related to cardiovascular morbidity 
(Baccarelli et al., 2010). Lower blood DNA methylation has been also found after 
exposure to traffic particles (Baccarelli et al., 2009) and after prolonged exposure to 
black carbon and SO4 particles (Madrigano et al., 2011). Other toxics associated with 
carcinogenesis, including asbestos, alcohol, radiation and arsenic, are known to act also 
by epigenetic mechanisms (Christensen and Marsit, 2011). However, as their 
importance in obesity pandemics is not well known, more studies in humans are 
necessary. One example is the result of a longitudinal analysis of the SUN cohort 
showing that recent ex-smokers and active smokers both experienced significantly 
greater weight gains than never-smokers (Basterra-Gortari et al., 2010). In this sense, 
exposure to cigarette smoke condensate induces changes in histone modifications in 
epithelial cells and immortalized bronchial epithelial cells (Liu et al., 2010), suggesting 
that epigenetics could play a role in smoking-cessation-induced weight gain. 
 
5.11. Infections 
In the last years, ten adipogenic pathogens have been associated with obesity in humans 
and in animals, including several viruses such as adenovirus 36 (Pasarica and 
Dhurandhar, 2007). However, although inflammation has been proposed as one of the 
triggering factors, the detailed cellular mechanism is unclear (Na and Nam, 2012). In 
this sense, it has been proposed that viral DNA insertion into established mammalian 
genomes is able to induce de novo DNA methylation of the integrate but also alterations 
of methylation patterns across the recipient genome (Doerfler, 2011). Although many 
efforts must be done to expand our knowledge on infectobesity, its real contribution to 
obesity pandemics is still unknown. 
On the other hand, among the numerous pathways and processes that are altered by 
obesity, impairment of the immune response is an important one (Marti et al., 2001). 
Thus, it has been hypothesized that altered immune cell metabolism and epigenetic 
modifications could influence the immune response to infectious disease in the obese 
host (Karlsson and Beck, 2010), and be responsible of the increased susceptibility to 
infection with a number of different pathogens. However, there are few reports 
observing the effect of nutritional factors on the epigenetic modification of immune 
cells and further studies are needed. 
 
5.12. Microbiome 
The microbiome plays a key role in a wide range of host-related processes, including 
obesity. This concept was demonstrated in an elegant experiment by Turnbaugh et al. 
(2006). They colonized with microbiota of genetically obese mice the gut of germ-free 
mice, and these mice significantly increased total body fat when compared with germ-
free counterparts colonized with microbiota from genetically lean mice. Low-grade 
inflammation due to metabolic endotoxemia is one of the candidates to link the gut 
microbiota with obesity, given that high levels of lipopolysaccharide and enhanced 
intestinal permeability have been found in obese and diabetic mice (Cani and Delzenne, 
2011). In this sense, lipopolysaccharide, a major component of the outer membrane of 
Gram-negative bacteria with potent inflammatory properties, induces de novo cytosine 
methylation in mouse embryonic fibroblasts (Tatemichi et al., 2008). On the other hand, 
lesions induced by lipopolysaccharide are attenuated with a pretreatment with butyrate, 
which has been attributed to an effect on inflammatory cytokine production (TNF-α, IL-
1β and nitric oxide) and NFκB activation (Ni et al., 2010). 
Although the effects of microbiome are found in the whole organism, colonic mucosa is 
the interface between the gut microbiota and the mammalian host. A new and exciting 
field in obesity research is the study of the epigenomic modifications associated with 
alterations in mucosal microbial composition (Kellermayer et al., 2011). For example, 
probiotics are being widely used in the prevention or treatment of chronic inflammatory 
conditions and are related with the production of short-chain fatty acids that regulate 
epigenetic processes (Licciardi et al., 2010). The few experiments performed in humans 
show that prebiotic, probiotic, and symbiotic dietary supplementation induce changes in 
fecal microbiota but did not significantly alter mucosal DNA methylation (Worthley et 
al., 2009). 
 
6. Physical activity 
Physical activity is one of the major links between the hormonal modulators of energy 
intake and output. Alongside with resting metabolic rate, it is a major contributor to 
maintain energy balance. For preventing obesity development, acute low- and moderate-
intensity exercise is usually recommended because it causes hormonal changes that 
facilitate lipolytic activity, probably by mediation of hormones (such as catecholamines, 
cortisol, insulin, growth hormone, and thyroid hormones), cytokines and oxidative 
stress (McMurray and Hackney, 2005).  
It is clear that physical activity confers many health benefits, and some of them may 
occur by alterations in epigenetic landscapes. Thus, Zhang et al. (2011a) have reported 
that, although the differences are small, individuals with high physical activity (30 
min/day) have a significantly higher level of global genomic DNA methylation in 
LINE-1 in peripheral blood than those with low physical activity (10 min/day). 
Unraveling the complexities of the histone code before and after exercise will 
undoubtedly reinforce the importance of skeletal muscle plasticity in health and disease. 
Thus, the class II HDACs 4, 5, 7, and 9 are known to play a key role in skeletal muscle 
development and adaptation and have been implicated in exercise adaptations (McGee 
and Hargreaves, 2011). As an example, after 60 minutes of exercise, changes have been 
observed in histone modifications associated with chromatin remodeling and 
transcriptional activation in human skeletal muscle (McGee et al., 2009). In rats, a 
single session of treadmill exercise reduces HDAC activity, increases HAT activity and 
increases the HAT/HDAC balance in rat hippocampus, suggesting that part of the 
neuroprotective effects of exercise could be mediated by epigenetic mechanisms (Elsner 
et al., 2011). 
As physical activity reduces the risk of breast cancer and other malignancies, several 
studies about the epigenetic modulation of gene expression due to physical activity have 
been carried out in oncology. For instance, physical activities for at least one year are 
inversely related to promoter hypermethylation of the tumor suppressor gene APC in 
breast cancer (Coyle et al., 2007). These studies in cancer suggest that exercise induces 
epigenetic modifications that could be behind its health beneficial effects. However, the 
mechanisms by which physical activity induces these modifications are far from being 
elucidated, with oxidative stress, changes in nutrient supply to the cells, inflammation or 
hormonal stimuli as some of the most likely contributors. 
As fetal period is more sensitive to epigenetic-induced alterations that could influence 
adult health status, much interest has arisen in the study of exercise during pregnancy. 
Thus, regular aerobic exercise during pregnancy seems to lead to a small reduction in 
offspring birth weight when compared with the offspring of nontraining women, which 
could be explained by maternal hormonal alterations, the regulation of nutrient 
availability for fetal growth through placenta, and epigenetic processes (Hopkins et al., 
2010). However, these effects on offspring growth were not associated with changes in 
maternal insulin sensitivity (during a healthy pregnancy) and no effects in offspring 
body composition were found (Hopkins et al., 2011). Anyway, the authors hypothesized 
that the reduction of offspring body weight may lead to a long-term reduction in the risk 
for obesity. 
 
7. Perinatal events (gestation and lactation) 
Established DNA methylation patterns are not immutable and can be modified during 
our lifetime by the environment (Kim KC et al., 2009; Martinez et al., 2012). However, 
it is well established that organ-specific DNA methylation patterns are established 
through epigenetic reprogramming during the fetal period and this is the period in which 
dietary and environmental factors play a major role. Indeed, a persistent change in early 
gene transcription may alter behavior and organ functions and be involved in the 
susceptibility and the age of onset of different metabolic disorders due to the in utero 
insult (Heerwagen et al., 2010). This is in relation with the concept of developmental 
plasticity, that enables an organism to adjust its phenotype to the environmental cues 
(Gluckman et al., 2009). A mismatch between the phenotypic outcome of adaptive 
plasticity and the current environment increases susceptibility to metabolic diseases and 
is the basis of the Developmental Origins of Health and Disease (DOHaD) hypothesis. 
This hypothesis postulate that unbalanced nutrition in utero and during infancy plays an 
important causative role in noncommunicable diseases, including diabetes, 
cardiovascular disease, allergy, some forms of cancer, cognitive decline, and affective 
disorders (Hanson and Gluckman, 2011). 
Although the whole perinatal period in which fetal development takes place is 
susceptible to epigenetic modifications, there is a period in which the epigenome seems 
to be more sensitive to environmental factors. After the fertilization methylation of 
specific sites is erased, and after the implantation methylation is restored by the 
gastrulation stage (Campion et al., 2009). Thus, at implantation, the DNA methylation 
patterns of individual promoters dynamically change and a study has identified by 
genome-wide analysis that de novo methylation occurs during implantation in 476 of 
691 promoters that are methylated in the E9.5 embryo (Borgel et al., 2010). However, it 
is also true that DNA methylation patterns established around implantation can be 
modified by further methylation or demethylation during subsequent stages of 
organogenesis as a result of environment factors that are not yet well known. An 
illustrative example is the effect of the phytoestrogen genistein, which has been 
described to mediate global changes in DNA methylation levels during mouse 
embryonic stem cell differentiation in the post gastrulation period but before germ layer 
differentiation (Sato et al., 2011). Genistein-induced epigenetic alterations seems to 
share important similarities with those found in intrauterine growth retardation neonates 
(Einstein et al., 2010), but the magnitude is markedly lower than the differences found 
between tissues or in cancer. As previously described, perinatal undernutrition (Jousse 
et al., 2011) or overnutrition (Plagemann et al., 2009), the intake of particular nutrients 
like methyl donors (Waterland et al., 2008) or PUFA (Kiec-Wilk et al., 2011), or the 
exposure to endocrine disruptors like bisphenol A (Rubin et al., 2011) are crucial in the 
in utero modulation of the epigenetic marks (DNA methylation or histone 
modifications), and more efforts must be made to unravel the epigenetic mechanisms 
involved in the pathogenesis of obesity and metabolic syndrome, including the doses of 
each compound, the interactions with the genotype and the period or length of the 
exposure. One interesting example of possible application of this research is the 
demonstration that leptin administration during the suckling period has protective 
effects against later obesity probably by inducing changes in promoter methylation of 
the hypothalamic POMC gene (Palou et al., 2011). 
These perinatal events are important in defining the epigenetic marks that will persist 
until the adult age. Some of these epigenetic marks could be used as early prognostic 
markers of disease to identify those individuals with more risk to develop a metabolic 
disorder. Thus, a recent report has evidenced that the methylation of different gene 
promoters (RXRA, eNOS) at birth is associated with child's later adiposity (Godfrey et 
al., 2011), suggesting that prenatal developmental may alter the epigenetic regulation of 
key components of metabolic disease risk and that a perinatal epigenetic analysis might 
identify subjects at high risk of developing later obesity. Another interesting result has 
been recently found when comparing cord blood global Long Interspersed Nucleotide 
Element-1 (LINE-1) methylation among newborns with low and high birth weight as 
well as among prematurely born infants, which might contribute to the increased risk of 
chronic diseases among individuals with these characteristics (Michels et al., 2011). 
Similarly, lower methylation of LINE-1 repetitive elements has been associated to 
higher risk for incident ischemic heart disease, stroke and total mortality (Baccarelli et 
al., 2010). 
 
8. Inheritance of epigenetic traits 
Apart from the higher availability of energy-dense foods, one of the hypothesis that try 
to explain the rising prevalence of obesity and hepatic steatosis is a feed-forward circle 
that may exacerbate these disorders throughout multiple generations. This hypothesis 
was audaciously postulated by McAllister et al. (2009), and, beyond genetics, they tried 
to explain it because obesity in women is associated with lower socioeconomic status, 
which has been linked to producing more offspring, and because there exists an 
assortative mating based on spousal resemblance in many physical characteristics, 
including body weight (Katzmarzyk et al., 1999). However, the intricate mechanisms 
are very difficult to demonstrate empirically in humans. 
In animals, it has been demonstrated that long-term exposure to a methyl donor rich diet 
for six generations results in a large number of loci exhibiting epigenetic variability, 
suggesting that some of the induced changes are heritable (Li CC et al., 2011). The 
offspring of HFD-fed mice are more susceptible to develop hepatic steatosis when 
weaned on the same HFD than on normal chow (Li J et al., 2011). The metabolic effects 
of maternal high-fat diet exposure on body length and insulin insensitivity persist also 
across at least two generations of offspring (Dunn et al., 2009). This may probably be 
explained due to transgenerational accumulation of epigenetic modifications leading to 
up-regulation of lipogenesis and endoplasmic reticulum stress in the liver. These 
epigenetic alterations are transmitted not only by the mother but also by the father, as 
demonstrated by Ng et al. (Ng et al., 2010), who observed that chronic HFD 
consumption in rat fathers induced increased body weight and adiposity, impaired 
glucose tolerance and insulin resistance in the female offspring. Other studies in rodents 
have evidenced the transgenerational progression of metabolic phenotypes through the 
male lineage, supporting thus a potential role for epigenetic mechanisms as a 
consequence of broad programming events at imprinted loci (Pertinat et al., 2010; Dunn 
and Bale, 2011), and changes in PPARα cytosine methylation due to paternal low-
protein diet (Carone et al., 2010). 
In 1987 the hypothesis of the inheritance of epigenetic defects was postulated (Holliday, 
1987), breaking away from the idea of inheritance as an exclusive matter of Mendelian 
genetics. It stated that epigenetic defects in germline cells can be usually repaired by 
recombination at meiosis but that some are transmitted to offspring. Since them, many 
evidences have been accumulated in the defence of this audacious postulate but only in 
the last few years there is more widespread acceptance of the theory. Although the 
molecular basis of this inheritance remains unclear, recent evidence points towards 
diffusible factors, in particular RNA, rather than DNA methylation or chromatin 
(Daxinger and Whitelaw, 2012). It seems that there are two crucial moments in which 
epigenetic information undergoes extensive reprogramming and becomes erased and re-
established: during gametogenesis and again in early embryogenesis, two events 
characterized by extensive changes in DNA methylation and chromatin modifications 
(Feng et al., 2010). However, there are some epigenetic marks that escape both 
incidences of reprogramming and are able to persist in the somatic cells of the 
individual. The knowledge of the mechanisms that participate in the protamine-, 
methylation-, histone- and small RNA-mediated inheritance will be of great importance 
in the understanding of the transgenerational inheritance of chronic non-communicable 
disease risk. 
 
9. Summary and future perspectives 
The state of the art in obesity research is that most of the cases of obesity are due to a 
combination of energy imbalance (higher energy intake than expenditure) with inherited 
genetic factors that, in conjunction with other hormonal and environmental signals, 
determines the individual predisposition to develop obesity and associated 
complications. However, emerging evidence suggests that one of the links between the 
environmental factors and the higher predisposition to develop obesity and metabolic 
syndrome is epigenetics. To date, there are evidences that many nutritional factors could 
act by modulating DNA methylation or histone modifications and some of them might 
be used in obesity therapy due, at least in part, to their epigenetic mechanisms (Fig. 3). 
This outcome is more evident in relation to the methyl donors (folate, methionine, 
choline and vitamins B6 and B12), especially when maternal diet is supplemented. 
Methyl donors are critical during fetal development, when they alter DNA methylation 
and influence neural precursor cell proliferation and correct brain development. The 
personalization of methyl donor necessities during pregnancy due to the genetic 
background is one of the most important tasks for the next few years. But also in the 
adult population there are differences in the health outcomes of methyl donor deficiency 
(fatty liver, insulin resistance) due to the common genetic variants. 
Other food components that have a promising future as epigenetic therapeutic agents 
against obesity and related disorders are polyphenols and organosulfur compounds. 
They have elicited very positive effects in cancer prevention and treatment, and many of 
them have been associated to lower risk of obesity, inflammation and oxidative stress. A 
careful investigation on the epigenetic properties of other nutrients, such as several fatty 
acids (particularly PUFA), minerals and vitamins, could open the door to new 
therapeutic approaches to combat obesity and its associated disorders. 
Another important research line concerns the applications of drugs targeting HATs, 
HDACs, or DNMTs as a novel therapy for diabetes. However, although in vitro and 
animal studies show encouraging results in different aspects (i.e. HDAC inhibitors 
enhance β-cell differentiation and survival and insulin signaling), a careful evaluation of 
the potential secondary effects is mandatory. The use of these drugs in obesity must 
reinforce even more the study of the secondary effects. 
Well designed and controlled in vitro and animal studies must be designed to 
understand the epigenetic mechanisms that modulate adipocyte differentiation, hepatic 
steatosis, insulin signaling, appetite regulation and insulin secretion, as well as 
important bioenergetic pathways, such as lipolysis, fat oxidation and glucose uptake and 
oxidation. In these studies, the epigenetic effects of inflammatory cytokines, reactive 
oxygen species, hypoxic conditions, high glucose levels, hormonal imbalance, 
endocrine disruptors and stress must be elucidated. 
Large, prospective studies are needed to understand whether changes in obesity risk 
factors, including the diet, physical exercise, stress and other environmental and 
metabolic factors, are associated with alterations in DNA methylation patterns or 
histone covalent modifications. Special emphasis must be laid on the effects of maternal 
environmental conditions on epigenetic regulation of gene expression and the long-term 
metabolic effects in the offspring. It is important to understand the perinatal epigenetic 
programming of the lifetime function of fundamental regulatory systems to successfully 
prevent diet-related metabolic diseases. 
On the other hand, microarray-based or sequencing approaches will be of great value for 
the identification of epigenetic biomarkers that can be used for early diagnosis of 
obesity, diabetes and cardiovascular diseases, and, in conjunction with other factors, for 
the design of further personalized therapeutic approaches (Fig. 4). As a major objective 
for the next 10 to 20 years, epigenetic knowledge should interact with genetic 
information, transcriptomic, proteomic and metabolomic data, and environmental 
variables to set the bases of a personalized treatment of metabolic diseases. The 
inheritance of these epigenetic marks is another issue that should be envisaged. 
To conclude, three ideas must be highlighted: 1) epigenetic mechanisms are involved in 
the onset and development of obesity and related metabolic dysfunctions; 2) the 
epigenetic marks could be useful in the prognosis and early diagnosis of obesity and 
related comorbidities; and 3) nutritional or pharmacological agents might be used as 
novel therapeutic strategies due to their ability to modulate the epigenetic processes, 
particularly during the perinatal period. In the next years, the research on obesity-related 
epigenetic mechanisms might help to prevent and control excessive fat deposition and 
insulin resistance by designing a personalized weight reduction plan. 
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Figure 1. Interactions among the different factors that are involved in the onset and 
development of obesity. 
 
 
 
 
Figure 2. Major epigenetic mechanisms involved in gene expression regulation. 
 
 
 
 
 
Figure 3. 
Metabolic, dietary and environmental factors that have been related to the regulation of 
adipogenesis and insulin sensitivity and may act by epigenetic mechanisms. 
 
 
 
 
Figure 4. Epigenetics as an important factor in personalized nutrition. 
 
Table 1. Some examples of key genes involving metabolic processes whose expression 
is controled by epigenetic mechanisms. 
 
 
 
Table 2. Some examples of metabolic effects attributed to nutritional factors acting 
through epigenetic processes. 
 
